WO2014099584A1 - Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment - Google Patents
Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment Download PDFInfo
- Publication number
- WO2014099584A1 WO2014099584A1 PCT/US2013/074584 US2013074584W WO2014099584A1 WO 2014099584 A1 WO2014099584 A1 WO 2014099584A1 US 2013074584 W US2013074584 W US 2013074584W WO 2014099584 A1 WO2014099584 A1 WO 2014099584A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfanyl
- pyridin
- thiazol
- amino
- carbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 218
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 50
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 213
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 130
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 116
- -1 { 2- [( { 3 - [(4-methoxyphenyl)sulf anyl] -6- [(4-methyl-4H- 1 ,2,4-triazol-3 -yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } sulfanyl Chemical group 0.000 claims description 106
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 94
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 54
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 27
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000001425 triazolyl group Chemical group 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- SDCSOIFJAIGHCH-UHFFFAOYSA-N ethyl 2-[5-[[3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carbonyl]amino]thiophen-2-yl]sulfanylacetate Chemical compound CCOC(=O)CSc1ccc(NC(=O)c2nc(Sc3ccc(F)cc3)ccc2Sc2ccc(F)cc2)s1 SDCSOIFJAIGHCH-UHFFFAOYSA-N 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- KOPZKACIIKMKDI-UHFFFAOYSA-N 2-[5-chloro-2-[[3-(4-fluorophenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-4-yl]acetic acid Chemical compound S1C(Cl)=C(CC(=O)O)N=C1NC(=O)C1=NC(SC=2N=CC=CC=2)=CC=C1SC1=CC=C(F)C=C1 KOPZKACIIKMKDI-UHFFFAOYSA-N 0.000 claims description 2
- SZYQPCWDTBUONO-UHFFFAOYSA-N 3-[2-[[3-(4-methoxyphenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-5-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1SC(C(=N1)C(=O)NC=2SC(CCC(O)=O)=CN=2)=CC=C1SC1=CC=CC=N1 SZYQPCWDTBUONO-UHFFFAOYSA-N 0.000 claims description 2
- ZTGMBVFCTYBKKE-UHFFFAOYSA-N ethyl 2-[2-[[3-(4-methoxyphenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NC(=O)C=2C(=CC=C(SC=3N=CC=CC=3)N=2)SC=2C=CC(OC)=CC=2)=N1 ZTGMBVFCTYBKKE-UHFFFAOYSA-N 0.000 claims description 2
- PRFUFAJCNPSTNX-UHFFFAOYSA-N ethyl 2-[[2-[[3-(4-fluorophenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetate Chemical compound S1C(SCC(=O)OCC)=CN=C1NC(=O)C1=NC(SC=2N=CC=CC=2)=CC=C1SC1=CC=C(F)C=C1 PRFUFAJCNPSTNX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- MVILWLLYYQVYNH-UHFFFAOYSA-N pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC=N1.NC(=O)C1=CC=CC=N1 MVILWLLYYQVYNH-UHFFFAOYSA-N 0.000 claims 2
- LBGJOPLJDBUTRE-UHFFFAOYSA-N 2-[5-chloro-2-[[3-(4-methoxyphenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-4-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1SC(C(=N1)C(=O)NC=2SC(Cl)=C(CC(O)=O)N=2)=CC=C1SC1=CC=CC=N1 LBGJOPLJDBUTRE-UHFFFAOYSA-N 0.000 claims 1
- VPMJAYKEXWWLHR-UHFFFAOYSA-N ethyl 2-[[2-[[3-(4-methoxyphenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetate Chemical compound S1C(SCC(=O)OCC)=CN=C1NC(=O)C1=NC(SC=2N=CC=CC=2)=CC=C1SC1=CC=C(OC)C=C1 VPMJAYKEXWWLHR-UHFFFAOYSA-N 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 abstract description 29
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 19
- 230000003213 activating effect Effects 0.000 abstract description 3
- 102000030595 Glucokinase Human genes 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 103
- 239000007787 solid Substances 0.000 description 81
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 74
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000003112 inhibitor Substances 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 239000000556 agonist Substances 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 102100029237 Hexokinase-4 Human genes 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 150000001408 amides Chemical class 0.000 description 25
- 230000008878 coupling Effects 0.000 description 25
- 238000010168 coupling process Methods 0.000 description 25
- 238000005859 coupling reaction Methods 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 238000001914 filtration Methods 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- 238000007127 saponification reaction Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000020477 pH reduction Effects 0.000 description 20
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 206010022489 Insulin Resistance Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 238000002207 thermal evaporation Methods 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 6
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 6
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 6
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 6
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 6
- 108010018763 Biotin carboxylase Proteins 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- 101000785259 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT2 Proteins 0.000 description 6
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 6
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000005548 Hexokinase Human genes 0.000 description 6
- 108700040460 Hexokinases Proteins 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 6
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 6
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- 102100028086 Neuromedin-S Human genes 0.000 description 6
- 101150014691 PPARA gene Proteins 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 6
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 6
- 239000005516 coenzyme A Substances 0.000 description 6
- 229940093530 coenzyme a Drugs 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 6
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 6
- 238000013265 extended release Methods 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 description 6
- 229950000991 ipragliflozin Drugs 0.000 description 6
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 6
- 108010021508 neuromedin S Proteins 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- PAVRPKIYSBJOOK-UHFFFAOYSA-N 3-(4-fluorophenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carboxylic acid Chemical compound C=1C=C(SC=2C=CC(F)=CC=2)C(C(=O)O)=NC=1SC1=CC=CC=N1 PAVRPKIYSBJOOK-UHFFFAOYSA-N 0.000 description 5
- BQWGUNMBAQEPKE-UHFFFAOYSA-N 3-(4-methoxyphenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1SC(C(=N1)C(O)=O)=CC=C1SC1=CC=CC=N1 BQWGUNMBAQEPKE-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960003345 empagliflozin Drugs 0.000 description 5
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- RIIDAVMUCMIWKP-AWEZNQCLSA-N 3-[(2s)-1-hydroxypropan-2-yl]oxy-n-(1-methylpyrazol-3-yl)-5-(4-methylsulfonylphenoxy)benzamide Chemical compound C=1C(C(=O)NC2=NN(C)C=C2)=CC(O[C@H](CO)C)=CC=1OC1=CC=C(S(C)(=O)=O)C=C1 RIIDAVMUCMIWKP-AWEZNQCLSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 4
- OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 4
- 229950000285 anacetrapib Drugs 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- 229950010046 avasimibe Drugs 0.000 description 4
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001906 cholesterol absorption Effects 0.000 description 4
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 4
- 229950007151 taspoglutide Drugs 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- QNLWMPLUWMWDMQ-YTTGMZPUSA-N (2s)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid Chemical compound N([C@@H](CC=1C=CC(OCCN2C3=CC=CC=C3C3=CC=CC=C32)=CC=1)C(=O)O)C1=CC=CC=C1C(=O)C1=CC=C(F)C=C1 QNLWMPLUWMWDMQ-YTTGMZPUSA-N 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 3
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 3
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 description 3
- NFTMKHWBOINJGM-UHFFFAOYSA-N 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole Chemical compound N1=CC(CC)=CN=C1N1CCC(C=2SC=C(COC=3C=CC(=CC=3)N3N=NN=C3)N=2)CC1 NFTMKHWBOINJGM-UHFFFAOYSA-N 0.000 description 3
- ZUGQWAYOWCBWGM-UHFFFAOYSA-N 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C(=CC(=CC=2)C(F)(F)F)F)SC=1CSC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZUGQWAYOWCBWGM-UHFFFAOYSA-N 0.000 description 3
- 108010092861 2-acylglycerol O-acyltransferase Proteins 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- WIUSRJIUQRFAHN-UHFFFAOYSA-N 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylic acid Chemical compound C=1C=C(SC=2C=CC(F)=CC=2)C(C(=O)O)=NC=1SC1=CC=C(F)C=C1 WIUSRJIUQRFAHN-UHFFFAOYSA-N 0.000 description 3
- KIZUBVPJNPVIIN-UHFFFAOYSA-N 3-[4-[2-[2-(cyanomethyl)phenyl]ethynyl]-2-fluorophenyl]propanoic acid Chemical compound C1=C(F)C(CCC(=O)O)=CC=C1C#CC1=CC=CC=C1CC#N KIZUBVPJNPVIIN-UHFFFAOYSA-N 0.000 description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 3
- AYJRTVVIBJSSKN-UHFFFAOYSA-N 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(COC=3C=NC(=CC=3)C=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 AYJRTVVIBJSSKN-UHFFFAOYSA-N 0.000 description 3
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 3
- IRNJSRAGRIZIHD-UHFFFAOYSA-N 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1C(=O)COC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 IRNJSRAGRIZIHD-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 101710190443 Acetyl-CoA carboxylase 1 Proteins 0.000 description 3
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 3
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 3
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 3
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 3
- 108010055448 CJC 1131 Proteins 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 3
- 229920000230 Colestilan Polymers 0.000 description 3
- 229920002911 Colestipol Polymers 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 3
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- 108010011459 Exenatide Proteins 0.000 description 3
- BZCALJIHZVNMGJ-HSZRJFAPSA-N Fasiglifam Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 3
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 3
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 description 3
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 101710154531 G-protein coupled bile acid receptor 1 Proteins 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 108010074394 GSK2374697 Proteins 0.000 description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 3
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 3
- 101000829138 Homo sapiens Somatostatin receptor type 3 Proteins 0.000 description 3
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 3
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108010089308 Insulin Detemir Proteins 0.000 description 3
- 108010057186 Insulin Glargine Proteins 0.000 description 3
- 108010065920 Insulin Lispro Proteins 0.000 description 3
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 3
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 3
- 229940122199 Insulin secretagogue Drugs 0.000 description 3
- 229940122355 Insulin sensitizer Drugs 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 3
- 108010019598 Liraglutide Proteins 0.000 description 3
- 108010007859 Lisinopril Proteins 0.000 description 3
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 3
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000030937 Neuromedin U receptor Human genes 0.000 description 3
- 108010002741 Neuromedin U receptor Proteins 0.000 description 3
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 3
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 3
- 102400000319 Oxyntomodulin Human genes 0.000 description 3
- 101800001388 Oxyntomodulin Proteins 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 3
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 3
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 3
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 3
- 102100023803 Somatostatin receptor type 3 Human genes 0.000 description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 3
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000002404 acyltransferase inhibitor Substances 0.000 description 3
- 229960004733 albiglutide Drugs 0.000 description 3
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 3
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 3
- 229950010157 aleglitazar Drugs 0.000 description 3
- 229960004601 aliskiren Drugs 0.000 description 3
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 3
- 229960001667 alogliptin Drugs 0.000 description 3
- 238000010640 amide synthesis reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 239000003529 anticholesteremic agent Substances 0.000 description 3
- 229940127226 anticholesterol agent Drugs 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229950010663 balaglitazone Drugs 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 229960000516 bezafibrate Drugs 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002802 bromocriptine Drugs 0.000 description 3
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 229960001713 canagliflozin Drugs 0.000 description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 3
- 229960001838 canakinumab Drugs 0.000 description 3
- 229960000932 candesartan Drugs 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229960002174 ciprofibrate Drugs 0.000 description 3
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001214 clofibrate Drugs 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 229960004095 colestilan Drugs 0.000 description 3
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 3
- 229960002604 colestipol Drugs 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 229960003834 dapagliflozin Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229960005175 dulaglutide Drugs 0.000 description 3
- 108010005794 dulaglutide Proteins 0.000 description 3
- 229950001279 elafibranor Drugs 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- 229960004563 eprosartan Drugs 0.000 description 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 3
- 229950006535 ertugliflozin Drugs 0.000 description 3
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 description 3
- 229950000005 evacetrapib Drugs 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical class C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 3
- 229960003627 gemfibrozil Drugs 0.000 description 3
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 3
- 229960004346 glimepiride Drugs 0.000 description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
- 229960001381 glipizide Drugs 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 229940045189 glucose-6-phosphate Drugs 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 125000005368 heteroarylthio group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 239000000859 incretin Substances 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 108010050259 insulin degludec Proteins 0.000 description 3
- 229960004225 insulin degludec Drugs 0.000 description 3
- 229960003948 insulin detemir Drugs 0.000 description 3
- 229960002869 insulin glargine Drugs 0.000 description 3
- 108700039926 insulin glulisine Proteins 0.000 description 3
- 229960000696 insulin glulisine Drugs 0.000 description 3
- 229960002068 insulin lispro Drugs 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229960002397 linagliptin Drugs 0.000 description 3
- 229960002701 liraglutide Drugs 0.000 description 3
- 229960002394 lisinopril Drugs 0.000 description 3
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960001093 lixisenatide Drugs 0.000 description 3
- 108010004367 lixisenatide Proteins 0.000 description 3
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 3
- 229950007685 lobeglitazone Drugs 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 229950004397 luseogliflozin Drugs 0.000 description 3
- 229950004994 meglitinide Drugs 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 229960001110 miglitol Drugs 0.000 description 3
- 229960003365 mitiglinide Drugs 0.000 description 3
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 3
- 229950001135 muraglitazar Drugs 0.000 description 3
- 229960000698 nateglinide Drugs 0.000 description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 3
- 229950003494 naveglitazar Drugs 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 3
- 229960001199 olmesartan medoxomil Drugs 0.000 description 3
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 229960005235 piperonyl butoxide Drugs 0.000 description 3
- 229960002797 pitavastatin Drugs 0.000 description 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 229960003611 pramlintide Drugs 0.000 description 3
- 108010029667 pramlintide Proteins 0.000 description 3
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- WPDCHTSXOPUOII-UHFFFAOYSA-N propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC2CCN(CC2)C(=O)OC(C)C)C(OC)=C1NC1=CC=C(S(C)(=O)=O)N=C1C WPDCHTSXOPUOII-UHFFFAOYSA-N 0.000 description 3
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 3
- 229960001455 quinapril Drugs 0.000 description 3
- 108700027806 rGLP-1 Proteins 0.000 description 3
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 3
- 229960003401 ramipril Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000002461 renin inhibitor Substances 0.000 description 3
- 229940086526 renin-inhibitors Drugs 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 229960000672 rosuvastatin Drugs 0.000 description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 3
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 3
- 229950006544 saroglitazar Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 3
- 229960004937 saxagliptin Drugs 0.000 description 3
- 108010033693 saxagliptin Proteins 0.000 description 3
- 229950011186 semaglutide Drugs 0.000 description 3
- 108010060325 semaglutide Proteins 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- 229950000737 sodelglitazar Drugs 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 108010048573 taspoglutide Proteins 0.000 description 3
- 229960005187 telmisartan Drugs 0.000 description 3
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 3
- 229950000034 teneligliptin Drugs 0.000 description 3
- 229950006667 tofogliflozin Drugs 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 3
- 229950004514 torcetrapib Drugs 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 3
- 229960001254 vildagliptin Drugs 0.000 description 3
- 229960001729 voglibose Drugs 0.000 description 3
- HUMARXMRTXDPPK-UHFFFAOYSA-N (2-amino-1,3-thiazol-5-yl) thiocyanate Chemical compound NC1=NC=C(SC#N)S1 HUMARXMRTXDPPK-UHFFFAOYSA-N 0.000 description 2
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 2
- YGDRQLYJJGEHCC-UHFFFAOYSA-N 6-chloro-3-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(Cl)=CC=C1F YGDRQLYJJGEHCC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 2
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001733 carboxylic acid esters Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- UGOJWGHBNPPCOK-UHFFFAOYSA-N ethyl 2-(2-amino-5-chloro-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC=1N=C(N)SC=1Cl UGOJWGHBNPPCOK-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NUSVDASTCPBUIP-UHFFFAOYSA-N (5-bromo-1,3-thiazol-2-yl)azanium;bromide Chemical compound [Br-].BrC1=C[NH2+]C(=N)S1 NUSVDASTCPBUIP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- PBFBGLBYZHLKHL-UHFFFAOYSA-N 2-(4-aminophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(N)C=C1 PBFBGLBYZHLKHL-UHFFFAOYSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- FYHBVTYDATZUEE-UHFFFAOYSA-N 3-bromo-2,2-dimethylpropanoic acid Chemical compound BrCC(C)(C)C(O)=O FYHBVTYDATZUEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- MLRAJZNPKPVUDQ-UHFFFAOYSA-N 3-sulfanyl-1,2-dihydrotriazole Chemical compound SN1NNC=C1 MLRAJZNPKPVUDQ-UHFFFAOYSA-N 0.000 description 1
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108700001281 BIM 51077 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- YNNKIQBVTLSYSN-UHFFFAOYSA-N CCOC(Cc(nc(NC(c1nc(Sc2nnc[n]2C)ccc1Sc1ccc(C(F)(F)F)cc1)=O)[s]1)c1Cl)=O Chemical compound CCOC(Cc(nc(NC(c1nc(Sc2nnc[n]2C)ccc1Sc1ccc(C(F)(F)F)cc1)=O)[s]1)c1Cl)=O YNNKIQBVTLSYSN-UHFFFAOYSA-N 0.000 description 1
- SWZCMNQWFGBZLP-UHFFFAOYSA-N COC(CCc1cnc(NC(c2nc(Sc3ccccn3)ccc2Sc(cc2)ccc2F)=O)[s]1)=O Chemical compound COC(CCc1cnc(NC(c2nc(Sc3ccccn3)ccc2Sc(cc2)ccc2F)=O)[s]1)=O SWZCMNQWFGBZLP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 229940122770 Neurotransmitter uptake inhibitor Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ABVQHDCAHJUSSP-UHFFFAOYSA-N OC(CCc1cnc(NC(c2nc(Sc3ccccn3)ccc2Sc(cc2)ccc2F)=O)[s]1)=O Chemical compound OC(CCc1cnc(NC(c2nc(Sc3ccccn3)ccc2Sc(cc2)ccc2F)=O)[s]1)=O ABVQHDCAHJUSSP-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- HUBANNPOLNYSAD-UHFFFAOYSA-N clopyralid Chemical compound OC(=O)C1=NC(Cl)=CC=C1Cl HUBANNPOLNYSAD-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- SHQNGLYXRFCPGZ-UHFFFAOYSA-N ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC(N)=N1 SHQNGLYXRFCPGZ-UHFFFAOYSA-N 0.000 description 1
- YLSVRTOGQZAGMJ-UHFFFAOYSA-N ethyl 2-[[2-[[3-(3,4-dichlorophenyl)sulfanyl-6-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carbonyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetate Chemical compound S1C(SCC(=O)OCC)=CN=C1NC(=O)C1=NC(SC=2N(C=NN=2)C)=CC=C1SC1=CC=C(Cl)C(Cl)=C1 YLSVRTOGQZAGMJ-UHFFFAOYSA-N 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- SZFDOLOIYIFWNF-UHFFFAOYSA-N ethyl 3-[[2-[[3-(4-fluorophenyl)sulfanyl-6-pyridin-2-ylsulfanylpyridine-2-carbonyl]amino]-1,3-thiazol-5-yl]sulfanyl]-2,2-dimethylpropanoate Chemical compound S1C(SCC(C)(C)C(=O)OCC)=CN=C1NC(=O)C1=NC(SC=2N=CC=CC=2)=CC=C1SC1=CC=C(F)C=C1 SZFDOLOIYIFWNF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000011661 metabolic syndrome X Diseases 0.000 description 1
- AUQDWNOSVDUIAT-UHFFFAOYSA-N methyl 5-bromo-4-oxopentanoate Chemical compound COC(=O)CCC(=O)CBr AUQDWNOSVDUIAT-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000003901 neurotransmitter uptake inhibitor Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950005022 taranabant Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
- the present invention relates to glucokinase activators.
- the present invention is directed to compounds useful for the treatment of diabetes, especially type 2 diabetes, as well as related diseases and conditions such as obesity and metabolic syndrome.
- Glucokinase (GK)(ATP: D-hexose 6-phosphotransferase, EC 2.7.1.1) is one of 4 types of hexokinase (hexokinase IV) in mammals.
- Hexokinase is an enzyme that acts in the first stage of the glycolytic pathway catalyzing the reaction from glucose to glucose 6-phosphate.
- Glucokinase is localized mainly in the liver and the beta cells of the pancreas where it controls the rate-determining step of glucose metabolism.
- hexokinase (I, ⁇ , and ⁇ ) other than glucokinase
- the enzyme activities are saturated at a 1 mM or lower concentration of glucose
- the Km of glucokinase for glucose is 8 mM, which value is proximate to the physiological blood sugar level. Therefore, the intracellular glucose metabolism is accelerated through glucokinase in response to the change of blood sugar level from normal (5 mM) to postprandial elevation (10-15 mM).
- mice in which the glucokinase gene has been destroyed result in death shortly after birth (Grupe A, et al., "Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis", Cell, 83, 1995, P.69-78.)
- the blood sugar level is decreased in normal and diabetic mice where glucokinase is generated in excess (Ferre T, et al., "Correction of diabetic alterations by glucokinase", Proceedings of the National Academy of Sciences of the U.S.A., 93, 1996, P.7225-7230).
- the reactions of the pancreatic beta cells and hepatocytes move toward decreasing the blood sugar level.
- glucokinase works as a glucose sensor in humans and plays an important role in glucose homeostasis. As such, it is believed that for a large number of type ⁇ diabetic patients, it may be possible to regulate blood sugar level utilizing a glucokinase sensor system.
- the disclosed glucokinase-activating substances are expectected to accelerate insulin secretion in the pancreatic beta cells, and accelerate sugar uptake and inhibit sugar release in liver. Thus, they are considered useful as therapeutic agents in the treatment of type ⁇ diabetes.
- glucokinase of the pancreatic beta cell type is localized in the brain of rats, particularly in the feeding center (ventromedial hypothalamus; VMH).
- VMH ventilation hypothalamus
- Feeding of rats is decreased when glucose is administered into the brain, while inhibition of the glucose metabolism by intracerebral administration of a glucose analog, glucosamine, causes hyperphagia. From electrophysiological experiments, it has been recognized that the glucose responsive neuron is activated in response to the physiological change of glucose concentration (5-20 mM), but its activity is inhibited by inhibiting the glucose metabolism with glucosamine.
- glucokinase-activating substance in VMH is expected to improve not only the blood sugar lever but also obesity which is a problem in a large number of type ⁇ diabetic patients.
- the present invention addresses compounds represented by the formula:
- the present invention further relates to methods of treating diabetes and related diseases and conditions. DETAILED DESCRIPTION OF THE INVENTION
- the present invention addresses the following compounds, compounds of (1)-
- R 1 and R 2 individually represent Ci_ 6 alkyl, 6- to 10-membered aryl group, 5- to 10- membered heteroaryl group, a 5- to 7- membered cycloalkyl group, or a 5- to 7-membered aliphatic heterocyclic group optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylC(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylS(O) 0 - 2 , S(O) 0 - 2 or arylC ⁇ alkyl, wherein alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci_ 6 alkyl is optionally substituted by
- ring A in addition to the -L-T substituent, is further optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, Ci_ 6 alkylS(O) 0 - 2 , CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylC(0)i_ 2 Ci_ 6 alkyl, S(0)o- 2 or arylCi_ 6 alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, Ci_ 6 alkyl or Ci_ 6 alkoxy where the alkyl and alkoxy substituents are optionally substituted by 1-6 halogens.
- 1-4 substituents independently selected from: halogen, Ci_ 6 alkyl or Ci_ 6 alkoxy where the alkyl and alkoxy substituents are optionally
- L represents Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, NR 3 R 4 , Ci_ 6 alkylNR 3 R 4 , S(0)o- 2 Ci_ 6 alkyl or S(0)o- 2 , wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci- 6 alkyl is optionally substituted by 1-6 halogens,
- T represents C0 2 R, CONR 3 R 4 , or P(0)(OR 5 ) 2
- R, R 3 , R 4 , and R 5 are individually selected from hydrogen or Ci_6alkyl.
- R 1 and R 2 individually represent 6- to 10-membered aryl group, 5- to 10- membered heteroaryl group, a 5- to 7- membered cycloalkyl group, or a 5- to 7-membered aliphatic heterocyclic group optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_6alkylC(0)i_2Ci_6alkyl, Ci_6alkylS(0)o-2, S(0)o- 2 or arylCi-6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci_ 6 alkyl is optionally substituted by 1-6 halogens;
- ring A in addition to the -L-T substituent, is further optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, Ci_ 6 alkylS(O) 0 -2, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylC(0)i_ 2 Ci_ 6 alkyl, S(0)o- 2 or arylCi_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, Ci_6alkyl or Ci_6alkoxy where the alkyl or alkoxy substituents are optionally substituted by 1-6 halogens.
- 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy
- L represents Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, NR 3 R 4 , Ci_ 6 alkylNR 3 R 4 , S(0)o- 2 Ci_6alkyl or S(0)o- 2 , wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci-6alkyl is optionally substituted by 1-6 halogens,
- T represents C0 2 R, CONR 3 R 4 , or P(0)(OR 5 ) 2 , and
- R, R 3 , R 4 , and R 5 are individually selected from hydrogen or Ci_6alkyl.
- R 1 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylC(0)i_ 2 Ci_ 6 alkyl, Ci_ 6 alkylS(O) 0 - 2 , S(O) 0 - 2 or arylC ⁇ alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci_ 6 alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
- R 1 is a phenyl group, isothiazolyl group, imidazolyl group, oxazolyl group, thiadiazolyl group, thienyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, furyl group, thiazolyl group, isoxazolyl group or pyrazolyl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C ⁇ alkyl, d ⁇ alkylOd ⁇ alkyl, C ⁇ alkoxy, CN, NR 3 R 4 , C(0) 1 _ 2 C 1 _ 6 alkyl, Ci- 6 alkylC(0)i- 2 Ci_ 6 alkyl, Ci_ 6 alkylS(0)o- 2 or S(0)o- 2 , wherein the alkyl and alkoxy substituents are further optionally substituted by
- R 1 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl, wherein Ci_ 6 alkyl is further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
- R 1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C ⁇ alkyl, C ⁇ alkylOC ⁇ alkyl, C ⁇ alkoxy, CN, NR 3 R 4 , C(0) 1 _ 2 C 1 _ 6 alkyl, C 1 _ 6 alkylC(0) 1 _ 2 C 1 _ 6 alkyl, Ci_ 6 alkylS(0)o- 2 or S(0)o- 2 , wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci_ 6 alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
- 1-4 substituents independently selected from: halogen, hydroxy, oxo, C ⁇ alkyl, C ⁇ alkylOC ⁇ alkyl, C ⁇ alkoxy, CN,
- R 1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl, wherein the alkyl is further optionally substituted by 1-6 halogen substituents; or a
- R 2 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from:
- halogen hydroxy, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6alkylC(0)i-2Ci_6alkyl, Ci_6alkylS(0)o-2 or S(0)o- 2 , wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6 alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
- R 2 is a phenyl group, isothiazolyl group, imidazolyl group, oxazolyl group, thiadiazolyl group, thienyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, furyl group, thiazolyl group, isoxazolyl group or pyrazolyl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_ 6 alkyl, Ci_ 6 alkylOCi_ 6 alkyl, Ci_ 6 alkoxy, CN, NR 3 R 4 , C(0)i_ 2 Ci_ 6 alkyl, Ci_ 6alkylC(0)i- 2 Ci_6alkyl, Ci_6alkylS(0)o- 2 or S(0)o- 2 , wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, hydroxy, Ci_ 6 al
- R 2 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, Ci_6alkoxy, or Ci_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
- ring A is thiazolyl or phenyl, substituted as described above for ring A; or a pharmaceutically acceptable salt thereof.
- the present invention also relates to pharmaceutical compositions comprising compounds of any of (l)-(23) and a pharmaceutically acceptable carrier. Additionally, the present invention relates to use of a compound of any of (l)-(23) in the manufacture of a medicament for use in treating obesity or diabetes.
- the present invention relates to the use of a compound of any of (l)-(23) in therapy, for example, in the treatment of diabetes.
- the present invention further relates to a method for the treatment of a obesity or diabetes comprising administering to an individual a pharmaceutical composition comprising a compound of any of (l)-(23).
- Another embodiment of the present invention includes a method of treating a condition selected from: (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16)
- neurodegenerative disease (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, (21) hypertension or other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to treat said condition.
- Yet another embodiment of the present invention include a method of treating a condition selected from: (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16)
- dipeptidyl peptidase-IV (DPP-4) inhibitors e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, MK-3102;
- insulin sensitizers including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) PPARa/ ⁇ dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those disclosed in WO 02/06
- PPARy partial agonists such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as GlumetzaTM, FortametTM, and GlucophageXRTM; and
- PTP-1B protein tyrosine phosphatase- IB (PTP-1B) inhibitors (e.g., ISIS-113715 and TTP814);
- insulin or insulin analogs e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro, SBS1000 and oral and inhalable formulations of insulin and insulin analogs
- amylin and amylin analogs e.g., pramlintide
- sulfonylurea and non- sulfonylurea insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- a-glucosidase inhibitors e.g., acarbose, voglibose and miglitol
- glucagon receptor antagonists e.g., NOXG15, LY2409021
- incretin mimetics such as GLP-1, GLP-1 analogs, derivatives, and mimetics
- GLP-1 receptor agonists e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ⁇ -51077, including intranasal, transdermal, and once-weekly formulations thereof
- oxyntomodulin and oxyntomodulin analogs and derivatives e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ⁇ -51077, including intranasal, transderma
- LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors
- bile acid sequestering agents e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran
- inhibitors of cholesterol absorption e.g., ezetimibe
- acyl CoA:cholesterol acyltransferase inhibitors e.g., avasimibe
- HDL-raising drugs e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
- agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
- antihypertensive agents such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), ⁇ - ⁇ receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
- ACE inhibitors e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril
- GKAs glucokinase activators
- inhibitors of 11 ⁇ -hydroxysteroid dehydrogenase type 1, e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199;
- CETP inhibitors e.g., anacetrapib, evacetrapib and torcetrapib
- inhibitors of fructose 1,6-bisphosphatase e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
- inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
- AMP-activated Protein Kinase activators such as MB1055, ETC
- GPR-109 other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
- (23) neuromedin U receptor agonists e.g., such as those disclosed in WO
- NMS neuromedin S
- GPR-105 antagonists e.g., such as those disclosed in WO 2009/000087;
- SGLT inhibitors e.g., ASP1941, SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI-10773, ertugliflozin, remogloflozin, TS-071, tofogliflozin, ipragliflozin, and LX-4211;
- TGR5 receptor also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR
- ileal bile acid transporter inhibitors (31) ileal bile acid transporter inhibitors; (32) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;
- PTP-1B protein tyrosine phosphatase- IB
- IL-lb antibodies e.g., XOMA052 and canakinumab
- GPR 120 agonists such as KDT501
- said compounds being administered to the patient in an amount that is effective to treat said condition.
- Alkyl as well as other groups having the prefix "alk”, such as alkoxy, and the like, means carbon chains which may be linear or branched, or combinations thereof, containing the indicated number of carbon atoms. If no number is specified, 1-6 carbon atoms are intended for linear and 3-7 carbon atoms for branched alkyl groups. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and the like.
- Alkoxy refers to an alkyl group linked to oxygen.
- Aryl alone or in combination, relates to a phenyl, naphthyl or indanyl group.
- the "aryl” is phenyl.
- the abbreviation "Ph” represents phenyl.
- Cycloalkyl means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated. If no number of atoms is specified, 3-7 carbon atoms are intended, forming 1-3 carbocyclic rings that are fused. “Cycloalkyl” also includes monocyclic rings fused to an aryl group in which the point of attachment is on the non-aromatic portion. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
- Heteroaryl (HAR) unless otherwise specified, means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from oxygen (“O"), sulfur (“S”) and nitrogen (“N”). Heteroaryls thus includes heteroaryls fused to other kinds of rings, such as aryls, cycloalkyls and heterocycles that are not aromatic.
- heteroaryl groups include: pyrrolyl or pyrrole, isoxazolyl or isoxazole, isothiazolyl or isothiazole, pyrazolyl or pyrazole, pyridyl, oxazolyl or oxazole, oxadiazolyl or oxadiazole, thiadiazolyl or thiadiazole, thiazolyl or thiazole, imidazolyl or imidazole, triazolyl or triazole, tetrazolyl or tetrazole, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl or benzisoxazole, benzoxazolyl or benzoazole, benzothiazolyl or benzothiazole, benzothiadiazolyl or benzothiadiazole, dihydrobenzofuranyl or dihydrobenzofurane, indolinyl or ind
- Heterocycle or “heterocyclic” refers to nonaromatic cyclic ring structures in which one or more atoms in the ring, the heteroatom(s), is an element other than carbon.
- Heteroatoms are typically O, S or N atoms.
- Halogen includes fluorine, chlorine, bromine and iodine.
- Substitution may be on any available carbon atom that results in a stable structure.
- that language includes all groups or substituents having that feature.
- use of the language "wherein the alkyl, alkoxy, NR 3 R 4 or S(0)o- 2 substituents are further optionally substituted" indicates that any substituents possessing an alkyl, alkoxy, NR 3 R 4 or S(0)o- 2 component can be substituted within that component.
- number ranges where provided expressly include each and every number in that range as a discrete embodiment.
- Atoms of the compounds described herein may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of any of (l)-(23).
- different isotopic forms of hydrogen (H) include protium (IK) and deuterium (3 ⁇ 4T).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may yield certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds of any of (l)-(23) described herein can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- Tautomers are defined as compounds that undergo rapid proton shifts from one atom of the compound to another atom of the compound.
- Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form known as keto-enol tautomers.
- the present invention therefore may be understood to include all stereoisomers of compounds of any of (l)-(23) and pharmaceutically acceptable salts thereof.
- Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral
- Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column.
- any enantiomer or diastereomer of a compound of any of (l)-(23) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
- some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds of the instant invention may form solvates with water or common organic solvents. Solvates, and in particular, the hydrates of the compounds of any of (l)-(23) are also included in the present invention.
- the disclosed compounds have glucokinase activation activity, and therefore they are useful as therapeutic agents and/or preventive agents for diabetes mellitus as well as for diabetic complication.
- Diabetic complication means diseases caused by development of diabetes mellitus and includes, for example, diabetic nephropathy, diabetic retinopathy, diabetic neurosis, diabetic arteriosclerosis, and so on.
- the compounds of the present invention are considered of potential utility in the treatment of both insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM).
- IDDM insulin dependent diabetes mellitus
- NIDDM non-insulin dependent diabetes mellitus
- Insulin dependent diabetes mellitus is a "multi-factorial autoimmune disease for which susceptibility is determined by environmental and genetic factors"; see Tisch, R. and McDevitt, H. (1996) Cell 85. 291-297. Insulin dependent diabetes mellitus is classified as type I and type II depending on the predisposition.
- Compounds disclosed herein may be used in the manufacture of medicaments for treating one or more of the following diseases or conditions, including, without limitation:
- noninsulin dependent diabetes mellitus type 2 diabetes
- neurological disorders such as Alzheimer's disease, schizophrenia, and impaired cognition
- hypertriglyceridemia (elevated levels of triglyceride-rich-lipoproteins);
- the present invention also relates to a method for the treatment and control of mixed or diabetic dyslipidemia, hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, and/or hypertriglyceridemia, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of any of (1)- (23) or a pharmaceutically acceptable salt thereof.
- the compound may be used alone or advantageously may be administered with a cholesterol biosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor (e.g., simvastatin, atorvastatin, and the like).
- the compound may also be used advantageously in combination with other lipid lowering drugs such as cholesterol absorption inhibitors (e.g., stanol esters, sterol glycosides or azetidinones such as ezetimibe), ACAT inhibitors (e.g., avasimibe), CETP inhibitors (e.g. anacetrapib), niacin, bile acid sequestrants, microsomal triglyceride transport inhibitors, and bile acid reuptake inhibitors.
- cholesterol absorption inhibitors e.g., stanol esters, sterol glycosides or azetidinones such as ezetimibe
- ACAT inhibitors e.g., avasimibe
- CETP inhibitors e.g. anacetrapib
- niacin niacin
- bile acid sequestrants e.g. anacetrapib
- microsomal triglyceride transport inhibitors e
- hypercholesterolemia atherosclerosis, hyperlipidemia, hypertriglyceridemia, dyslipidemia, high LDL, and low HDL.
- Another aspect of the invention provides a method for the treatment and control of obesity or metabolic syndrome, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of (l)-(23).
- the compound may be used alone or advantageously may be administered with an anti-obesity agent, such as a lipase inhibitor (e.g., orlistat,) or a monoamine neurotransmitter uptake inhibitor (e.g., sibutramine or phentermine).
- an anti-obesity agent such as a lipase inhibitor (e.g., orlistat,) or a monoamine neurotransmitter uptake inhibitor (e.g., sibutramine or phentermine).
- the compound may also be used advantageously in combination with CB-1 inverse agonists or antagonists (e.g., rimonabant or taranabant).
- the present invention further relates to a method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient a compound of any of (l)-(23) in an amount that is effective to treat hyperglycemia, diabetes or insulin resistance.
- Yet another aspect of the invention that is of interest relates to a method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound of any of (l)-(23) in an amount that is effective to treat atherosclerosis.
- Yet another aspect of the invention that is of interest relates to a method of delaying the onset of one of the aforementioned conditions and disorders where insulin resistance is a component in a mammalian patient in need thereof, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to delay the onset of said condition.
- Yet another aspect of the invention that is of interest relates to a method of reducing the risk of developing one of the aforementioned conditions and disorders where insulin resistance is a component in a mammalian patient in need thereof, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to reduce the risk of developing said condition.
- Yet another aspect of the invention that is of interest relates to a method of treating a condition or reducing the risk of developing a condition or delaying the onset of a condition selected from the group consisting of (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, (21) hypertension and other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to treat said condition, and a compound selected from the group
- DPP-4 dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, omarigliptin);
- insulin sensitizers including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) PPARa/ ⁇ dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those disclosed in WO 02/06
- amylin and amylin analogs e.g., pramlintide
- sulfonylurea and non- sulfonylurea insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- a-glucosidase inhibitors e.g., acarbose, voglibose and miglitol
- glucagon receptor antagonists e.g., NOXG15, LY2409021
- incretin mimetics such as GLP-1, GLP-1 analogs, derivatives, and mimetics
- GLP-1 receptor agonists e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ⁇ -51077, including intranasal, transdermal, and once-weekly formulations thereof
- oxyntomodulin and oxyntomodulin analogs and derivatives e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ⁇ -51077, including intranasal, transderma
- LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors
- bile acid sequestering agents e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran
- inhibitors of cholesterol absorption e.g., ezetimibe
- acyl CoA:cholesterol acyltransferase inhibitors e.g., avasimibe
- HDL-raising drugs e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
- agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
- antihypertensive agents such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), ⁇ - ⁇ receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
- ACE inhibitors e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril
- ⁇ - ⁇ receptor blockers e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisart
- GKAs glucokinase activators
- AZD6370 glucokinase activators
- 11 ⁇ -hydroxysteroid dehydrogenase type 1 e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199
- CETP inhibitors e.g., anacetrapib, evacetrapib and torcetrapib
- inhibitors of fructose 1,6-bisphosphatase e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
- inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
- AMP-activated Protein Kinase activators such as MB1055, ETC
- GPR-109 other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
- (23) neuromedin U receptor agonists e.g., such as those disclosed in WO
- NMS neuromedin S
- GPR-105 antagonists e.g., such as those disclosed in WO 2009/000087;
- SGLT inhibitors e.g., ASP1941, SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI-10773, ertugliflozin, remogloflozin, TS-071, tofogliflozin, ipragliflozin, and LX-4211;
- TGR5 receptor also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR
- PACAP PACAP
- PACAP mimetics PACAP
- PACAP receptor 3 agonists PACAP, PACAP mimetics, and PACAP receptor 3 agonists
- PTP-1B protein tyrosine phosphatase- IB
- IL-lb antibodies e.g., XOMA052 and canakinumab
- any suitable route of administration may be employed for providing a mammal, especially a human, with an effective amount of a compound of the present invention.
- Dosage forms may include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- compounds of any of (1)- (23) are administered orally.
- the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
- the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
- the total daily dosage is from about 1.0 milligrams to about 1000 milligrams.
- the total daily dose will generally be from about 1 milligram to about 350 milligrams.
- the dosage for an adult human may be as low as 0.1 mg.
- the dosage regimen may be adjusted within this range or even outside of this range to provide the optimal therapeutic response.
- Oral administration will usually be carried out using tablets or capsules. Examples of doses in tablets and capsules are 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 25 mg, 50 mg, 100 mg, 200 mg, 350 mg, 500 mg, 700 mg, 750 mg, 800 mg and 1000 mg.
- Other oral forms may also have the same or similar dosages.
- compositions of the present invention comprise a compound of any of (l)-(23) in combination with a pharmaceutically acceptable carrier.
- the pharmaceutical compositions of the present invention comprise a compound of any of (l)-(23) as an active ingredient, as well as a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds described herein which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds described herein include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, edetate, edisylate, estolate, esylate, formate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride,
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N- di
- a pharmaceutical composition may also comprise a prodrug, or a pharmaceutically acceptable salt thereof, if a prodrug is administered.
- compositions are typically suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the particular active ingredient selected. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art. In practical use, compounds of any of (l)-(23) can be combined as the active ingredient in intimate admixture with the pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral
- compositions for oral dosage form any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid
- preparations such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
- tablets and capsules represent the most advantageous oral dosage form.
- Solid pharmaceutical carriers are therefore typically employed.
- tablets may be coated by standard aqueous or nonaqueous techniques.
- Such compositions and preparations typically comprise at least about 0.1 percent of active compound, the remainder of the composition being the carrier.
- the percentage of active compound in these compositions may, of course, be varied and is conveniently between about 2 percent to about 60 percent of the weight of the dosage form. The amount of active compound in such
- therapeutically useful compositions is such that an effective dosage will be delivered.
- the active compound can be administered intranasally as, for example, in the form of liquid drops or a spray.
- the tablets, capsules and the like also typically contain a binder.
- suitable binders include gum tragacanth, acacia, gelatin and a synthetic or semisynthetic starch derivative, such as hydroxypropylmethylcellulose (HPMC); excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and in some instances, a sweetening agent such as sucrose, lactose or saccharin.
- a liquid carrier such as fatty oil.
- tablets may be coated with shellac, sugar or both.
- Syrups and elixirs typically contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl or propylparabens as a preservative, a dye and a flavoring such as cherry or orange flavor.
- the compounds of any of (l)-(23) may also be administered parenterally.
- Solutions or suspensions of these active compounds can be prepared in water, saline or another biocompatible vehicle, suitably mixed with a surfactant, buffer, and the like. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in an oil. Under ordinary conditions of storage and use, these preparations can also contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions and dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions and dispersions.
- the preparation should be prepared under sterile conditions and be fluid to the extent that easy syringability exists. It should be sufficiently stable under the conditions of manufacture and storage and preserved against the growth of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and suitable oils.
- compounds of the present invention may be used in combination with other drugs that may also be useful in the treatment or amelioration of the individual diseases and conditions described herein.
- Such other drugs may be administered by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of any of (l)-(23).
- more than one drug is commonly administered.
- the compounds of this invention may generally be administered to a patient who is already taking one or more other drugs for these conditions.
- the combination therapy also includes therapies in which a compound of any of (l)-(23) and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compound of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of any of (l)-(23). Examples of other active ingredients that may be administered separately or in the same pharmaceutical composition in combination with a compound of any of (l)-(23) include, but are not limited to:
- dipeptidyl peptidase-IV (DPP-4) inhibitors e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, MK-3102;
- insulin sensitizers including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, PPARa/ ⁇ aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those disclosed in WO 02/06
- insulin or insulin analogs e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro, SBS1000 and oral and inhalable formulations of insulin and insulin analogs
- amylin and amylin analogs e.g., pramlintide
- sulfonylurea and non- sulfonylurea insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- insulin secretagogues e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide
- a-glucosidase inhibitors e.g., acarbose, voglibose and miglitol
- glucagon receptor antagonists e.g., NOXG15, LY2409021
- incretin mimetics such as GLP-1, GLP-1 analogs, derivatives, and mimetics
- GLP-1 receptor agonists e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and BIM-51077, including intranasal, transdermal, and once-weekly formulations thereof
- oxyntomodulin and oxyntomodulin analogs and derivatives e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and BIM-51077, including intranasal, transderma
- LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin), (ii) bile acid sequestering agents (e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe), and (iv) acyl CoA:cholesterol acyltransferase inhibitors, (e.g., avasimibe);
- HMG-CoA reductase inhibitors e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastat
- HDL-raising drugs e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
- agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
- antihypertensive agents such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), ⁇ - ⁇ receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
- ACE inhibitors e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril
- ⁇ - ⁇ receptor blockers e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisart
- GKAs glucokinase activators
- inhibitors of 11 ⁇ -hydroxysteroid dehydrogenase type 1, e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199;
- CETP inhibitors e.g., anacetrapib, evacetrapib and torcetrapib
- inhibitors of fructose 1,6-bisphosphatase e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
- inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
- AMP-activated Protein Kinase activators such as MB1055, ETC
- GPR-109 other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
- (23) neuromedin U receptor agonists e.g., such as those disclosed in WO
- NMS neuromedin S
- GPR-105 antagonists e.g., such as those disclosed in WO 2009/000087
- SGLT inhibitors e.g., ASP1941 , SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI- 10773, ertugliflozin, remogloflozin, TS-071 , tofogliflozin, ipragliflozin, and LX-421 1
- SGLT inhibitors e.g., ASP1941 , SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI- 10773, ertugliflozin, remogloflozin, TS-071 , tofogliflozin, ipragliflozin, and LX-421 1
- TGR5 receptor also known as GPBAR1 , BG37, GPCR19, GPR131 , and M-BAR
- PACAP PACAP
- PACAP mimetics PACAP
- PACAP receptor 3 agonists PACAP, PACAP mimetics, and PACAP receptor 3 agonists
- IL- lb antibodies e.g., XOMA052 and canakinumab
- GPR 120 agonists such as KDT501.
- Another aspect of the invention that is of interest relates to the use of a compound of any of (l)-(23) in the manufacture of a medicament for use in treating a disease or condition described herein.
- the glucokinase-activating capability of the compounds (I) may be determined according to methods previously described (e.g., Diabetes, 45, 1671- 1677, 1996).
- the glucokinase activity can, for instance, be determined without directly measuring glucose-6-phosphate by measuring the amount of Thio-NADH generated during the production of phosphogluconolactone from glucose-6-phosphate by a reporter enzyme glucose-6- phosphate dehydrogenase.
- Recombinant human liver glucokinase was expressed as a FLAG fusion protein in E.coli, and purified on ANTIFLAG M2 AFFINITY GEL (Sigma).
- the OD values of the respective compounds were measured in the respective concentrations, wherein the OD value of DMSO as control is regarded as 100%. From the OD values at the respective concentrations, Emax (%, 2.5 mM Glu) and EC50 (nM, 2.5 mM Glu) were calculated and used as indicators of the GK activation capability of the compounds.
- the compounds of the present invention have sufficient GK activation capability when Emax and EC50 are employed as indicators. Furthermore, the disclosed and exemplified compounds have the potential to be more liver-preferring over the pancreas, enabling the disclosed and exemplified compounds to potentially reduce the risk of hypoglycemia in individuals being treated.
- the compounds of the invention can be prepared using the synthetic schemes described herein as well as any of several alternate methods which will be apparent to a chemist skilled in the art.
- the following abbreviations may be used in the synthetic schemes or
- THF is tetrahydrofuran
- TLC is thin layer chromatography
- TNAD is thionicotinaniide-adenine dinucleotide.
- Certain compounds of formula I in the invention may be prepared starting from the compound of formula VII by Method A as shown in the following Reaction Scheme.
- Method A A person of skilled in the art will understand that additional methods may also be used.
- a person skilled in the art will appreciate that alternative reagents, temperatures and solvents may be used to effect the same transformation.
- the compounds of the invention can be made using organic synthesis using starting materials, reagents and reactions well known in the art.
- Xi and X 2 are functional groups that will be converted into aryl- or heteroaryl-thio groups, preferably chloro or fluoro;
- R 1 , R 2 , R 3 , R 4 , L, T and X are as above.
- the carboxylic acids of formula VII wherein Xi and X 2 are both chloro is commercially available.
- the carboxylic acids of formula VII wherein Xi is fluoro and X 2 is chloro is also commercially available.
- the carboxylic acids can be converted to the
- resulting compound VI may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
- the Xi group of formula VI can be displaced by an arylthio group in the presence of a base, such as potassium carbonate and cesium carbonate, in a polar solvent, such as DMF, at ambient temperature or a slightly higher temperature.
- a base such as potassium carbonate and cesium carbonate
- a polar solvent such as DMF
- resulting compound V may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
- the X 2 group of formula V can be displaced by an arylthio or heteroaryl thio group in the presence of a base, such as potassium tert-butoxide, potassium carbonate and cesium carbonate, in a polar solvent, such as DMF and DMA, usually at higher temperature.
- a base such as potassium tert-butoxide, potassium carbonate and cesium carbonate
- a polar solvent such as DMF and DMA
- resulting compound IV may be isolated and purified by conventional means, for example, concentration extraction, vacuum condensation, chromatography, and so on.
- the ieri-butyl ester prepared from Step 3 can be converted to the corresponding carboxylic acid by the treatment of a strong acid, such as TFA, HC1 and so on.
- resulting compound III may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- the compound III may be used in the subsequent step without purification.
- acid III is allowed to react with the amino compound (II) to give compound I.
- the reaction may be carried by performing amide-formation reactions by a method as described previously (for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
- resulting compound I may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- Step 6 compound I wherein T is an carboxylic ester group may be saponified by the treatment of a base followed by acidification to give the corresponding carboxylic acid 1-1.
- the base used in this step may be alkali hydroxides, such as lithium hydroxide and sodium hydroxide.
- resulting compound 1-1 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- carboxylic acid 1-1 is allowed to reacted with an amine to give the corresponding carboxamde.
- the reaction may be carried by performing amide-formation reactions by a method as described previously for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
- resulting compound 1-2 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- compound I wherein T is an carboxylic ester group may be transformed into the corresponding carboxamide 1-2 by heating with an amine or by the reaction with an amine in the presence of a Lewis acid, such as trimethylaluminum, etc, with or without heating.
- a Lewis acid such as trimethylaluminum, etc
- resulting compound 1-2 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- certain compounds of formula I in the invention may be prepared starting from the compound of formula X by Method B as shown in the following Reaction Scheme.
- acid X is allowed to react with the amino compound (II) to give compound IX.
- the reaction may be carried by performing amide-formation reactions by a method as described previously (for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
- resulting compound IX may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
- the Xi group of formula IX can be displaced by an arylthio group in the presence of a base, such as potassium carbonate and cesium carbonate, in a polar solvent, such as DMF, at ambient temperature or a slightly higher temperature.
- a base such as potassium carbonate and cesium carbonate
- a polar solvent such as DMF
- resulting compound VIII may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
- the X 2 group of formula VIII can be displaced by an arylthio or heteroaryl thio group in the presence of a base, such as potassium tert-butoxide, potassium carbonate and cesium carbonate, in a polar solvent, such as DMF and DMA, usually at higher temperature.
- a base such as potassium tert-butoxide, potassium carbonate and cesium carbonate
- a polar solvent such as DMF and DMA
- resulting compound I may be isolated and purified by conventional means, for example, concentration extraction, vacuum condensation, chromatography, and so on.
- Acetyl chloride (5.45 mL, 76.0 mmol) was added slowly to anhydrous ethanol (70 mL) with stirring at 0 °C to generate a solution of HCl in ethanol.
- the solution was added to a solution of the crude product above in ethanol (30 mL) and stirred for 18 h at 50 °C. Most solvent was removed in vacuo and the residue was purified by flash column chromatography to give the title compound as a brown solid (4.58 g, 69%).
- Example 44 the title compound (41.8 mg, 70.3%) was obtained as a yellow solid from the amide coupling of 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3- ⁇ [4- (trifluoromethyl)phenyl] sulf anyl ⁇ pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl [(2-amino- l ,3-thiazol-5-yl)sulfanyl]acetate (27.5 mg, 0.126 mmol) and purified by HLPC. ESI- MS (m/e): 612.8 [M+H] + .
- Example 44 the title compound (41.8 mg, 70.3%) was obtained as a yellow solid from the amide coupling of 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3- ⁇ [4- (trifluoromethyl)phenyl] sul
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
Description
NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT
FIELD OF THE INVENTION
The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
BACKGROUND OF THE INVENTION
The present invention relates to glucokinase activators. In particular, the present invention is directed to compounds useful for the treatment of diabetes, especially type 2 diabetes, as well as related diseases and conditions such as obesity and metabolic syndrome.
Glucokinase (GK)(ATP: D-hexose 6-phosphotransferase, EC 2.7.1.1) is one of 4 types of hexokinase (hexokinase IV) in mammals. Hexokinase is an enzyme that acts in the first stage of the glycolytic pathway catalyzing the reaction from glucose to glucose 6-phosphate. Glucokinase is localized mainly in the liver and the beta cells of the pancreas where it controls the rate-determining step of glucose metabolism. Notably, in 3 types of hexokinase (I, Π, and ΠΙ) other than glucokinase, the enzyme activities are saturated at a 1 mM or lower concentration of glucose, whereas the Km of glucokinase for glucose is 8 mM, which value is proximate to the physiological blood sugar level. Therefore, the intracellular glucose metabolism is accelerated through glucokinase in response to the change of blood sugar level from normal (5 mM) to postprandial elevation (10-15 mM).
Results in recombinant mice expressing glucokinase have demonstrated that in fact glucokinase plays an important role in the generalized homeostasis of glucose. Though mice in which the glucokinase gene has been destroyed result in death shortly after birth (Grupe A, et al., "Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis", Cell, 83, 1995, P.69-78.), the blood sugar level is decreased in normal and diabetic mice where glucokinase is generated in excess (Ferre T, et al., "Correction of diabetic alterations by glucokinase", Proceedings of the National Academy of Sciences of the U.S.A., 93, 1996, P.7225-7230). With increase of the glucose concentration, the reactions of the pancreatic beta cells and hepatocytes move toward decreasing the blood sugar level.
This means that glucokinase works as a glucose sensor in humans and plays an important role in glucose homeostasis. As such, it is believed that for a large number of type Π
diabetic patients, it may be possible to regulate blood sugar level utilizing a glucokinase sensor system.
The disclosed glucokinase-activating substances are expectected to accelerate insulin secretion in the pancreatic beta cells, and accelerate sugar uptake and inhibit sugar release in liver. Thus, they are considered useful as therapeutic agents in the treatment of type Π diabetes.
It has furthermore been elucidated that the occurrence of glucokinase of the pancreatic beta cell type is localized in the brain of rats, particularly in the feeding center (ventromedial hypothalamus; VMH). About 20 % of the neurocytes in VMH, called the glucose responsive neuron, are believed to play an important role in control of body weight. Feeding of rats is decreased when glucose is administered into the brain, while inhibition of the glucose metabolism by intracerebral administration of a glucose analog, glucosamine, causes hyperphagia. From electrophysiological experiments, it has been recognized that the glucose responsive neuron is activated in response to the physiological change of glucose concentration (5-20 mM), but its activity is inhibited by inhibiting the glucose metabolism with glucosamine. The same mechanism through glucokinase has been assumed in the sensor system for the glucose concentration in VHM as in the insulin secretion in the pancreatic beta cells. Therefore, in addition to the action in the liver and pancreatic beta cells, a glucokinase-activating substance in VMH is expected to improve not only the blood sugar lever but also obesity which is a problem in a large number of type Π diabetic patients.
SUMMARY OF THE INVENTION
The present invention addresses compounds represented by the formula:
and pharmaceutically acceptable salts thereof. The present invention further relates to methods of treating diabetes and related diseases and conditions.
DETAILED DESCRIPTION OF THE INVENTION
The present invention addresses the following compounds, compounds of (1)-
(23):
(1) A compound of the formula (I):
(I) or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 individually represent Ci_6alkyl, 6- to 10-membered aryl group, 5- to 10- membered heteroaryl group, a 5- to 7- membered cycloalkyl group, or a 5- to 7-membered aliphatic heterocyclic group optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_ 6alkyl, Ci_6alkylC(0)i_2Ci_6alkyl, Ci_6alkylS(O)0-2, S(O)0-2 or arylC^alkyl, wherein alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens;
ring A represents a 5- to 7-membered monocyclic or 9- to 10-membered bicyclic heteroaryl group in which the carbon atom attached to the amide nitrogen atom contained in formula (I) forms C=N together with the nitrogen atom in the ring,
wherein ring A, in addition to the -L-T substituent, is further optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_ 6alkylOCi_6alkyl, Ci_6alkoxy, Ci_6alkylS(O)0-2, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_6alkylC(0)i_2Ci_ 6alkyl, S(0)o-2 or arylCi_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, Ci_6alkyl or Ci_6alkoxy where the alkyl and alkoxy substituents are optionally substituted by 1-6 halogens.
L represents Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, NR3R4, Ci_6alkylNR3R4, S(0)o-2Ci_6alkyl or S(0)o-2, wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci-6alkyl is optionally substituted by 1-6 halogens,
T represents C02R, CONR3R4, or P(0)(OR5)2, and
R, R3, R4, and R5 are individually selected from hydrogen or Ci_6alkyl.
(2) A compound of the formula (I):
(I) or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 individually represent 6- to 10-membered aryl group, 5- to 10- membered heteroaryl group, a 5- to 7- membered cycloalkyl group, or a 5- to 7-membered aliphatic heterocyclic group optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_ 6alkyl, Ci_6alkylC(0)i_2Ci_6alkyl, Ci_6alkylS(0)o-2, S(0)o-2 or arylCi-6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens;
ring A represents a 5- to 7-membered monocyclic or 9- to 10-membered bicyclic heteroaryl group in which the carbon atom attached to the amide nitrogen atom contained in formula (I) forms C=N together with the nitrogen atom in the ring,
wherein ring A, in addition to the -L-T substituent, is further optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_ 6alkylOCi_6alkyl, Ci_6alkoxy, Ci_6alkylS(O)0-2, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_6alkylC(0)i_2Ci_ 6alkyl, S(0)o-2 or arylCi_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, Ci_6alkyl or Ci_6alkoxy where the alkyl or alkoxy substituents are optionally substituted by 1-6 halogens.
L represents Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, NR3R4, Ci_6alkylNR3R4, S(0)o-2Ci_6alkyl or S(0)o-2, wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci-6alkyl is optionally substituted by 1-6 halogens,
T represents C02R, CONR3R4, or P(0)(OR5)2, and
R, R3, R4, and R5 are individually selected from hydrogen or Ci_6alkyl.
(3) A compound of (1) or (2), wherein R1 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_ 6alkylC(0)i_2Ci_6alkyl, Ci_6alkylS(O)0-2, S(O)0-2 or arylC^alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
(4) A compound of any of (l)-(3), wherein R1 is a phenyl group, isothiazolyl group, imidazolyl group, oxazolyl group, thiadiazolyl group, thienyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, furyl group, thiazolyl group, isoxazolyl group or pyrazolyl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C^alkyl, d^alkylOd^alkyl, C^alkoxy, CN, NR3R4, C(0)1_2C1_6alkyl, Ci-6alkylC(0)i-2Ci_6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
(5) A compound of any of (l)-(4), wherein R1 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen or Ci_6alkyl, wherein Ci_6alkyl is further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
(6) A compound of any of (l)-(5), wherein R1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C^alkyl, C^alkylOC^alkyl, C^alkoxy, CN, NR3R4, C(0)1_2C1_6alkyl, C1_6alkylC(0)1_2C1_ 6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
(7) A compound of any of (l)-(6), wherein R1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen or Ci_6alkyl, wherein the alkyl is further optionally substituted by 1-6 halogen substituents; or a
pharmaceutically acceptable salt thereof.
(8) A compound of any of (l)-(7), wherein R1 is triazolyl substituted with a methyl group; or a pharmaceutically acceptable salt thereof.
(9) A compound of any of (l)-(7), wherein R1 is pyridyl; or a pharmaceutically acceptable salt thereof.
(10) A compound of any of (l)-(7), wherein R1 is phenyl substituted with fluorine; or a pharmaceutically acceptable salt thereof.
(11) A compound of any of (1)-(10), wherein R2 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from:
halogen, hydroxy, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_ 6alkylC(0)i-2Ci_6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
(12) A compound of any of (l)-(l 1), wherein R2 is a phenyl group, isothiazolyl group, imidazolyl group, oxazolyl group, thiadiazolyl group, thienyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, furyl group, thiazolyl group, isoxazolyl group or pyrazolyl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_ 6alkylC(0)i-2Ci_6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
(13) A compound of any of (1)-(12), wherein R2 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, Ci_6alkoxy, or Ci_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
(14) A compound of any of (1)-(13), wherein ring A is a 5-6-membered aryl or heteroaryl group, substituted as described above for ring A; or a pharmaceutically acceptable salt thereof.
(15) A compound of any of (1)-(14), wherein ring A is a phenyl group, isothiazolyl group, imidazolyl group, oxazolyl group, thiadiazolyl group, thienyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidinyl group, furyl group, thiazolyl group, isoxazolyl group or pyrazolyl group, substituted as described above for ring A; or a pharmaceutically acceptable salt thereof.
(16) A compound of any of (1)-(15), wherein ring A is thiazolyl or phenyl, substituted as described above for ring A; or a pharmaceutically acceptable salt thereof.
(17) A compound of any of (1)-(16), wherein ring A is thiazolyl or phenyl, substituted by -L-T; or a pharmaceutically acceptable salt thereof.
(18) A compound of any of (1)-(17), wherein L represents Ci-6alkyl or S(0)o-2Ci_
6alkyl, further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
(19) A compound of any of (1)-(18), wherein L represents -SCH2-, SC(CH3)2-, - SCH2C(CH3)2-, -CH2CH2- or -CH2-; or a pharmaceutically acceptable salt thereof.
(20) A compound of any of (1)-(19) wherein T is C02R; or a pharmaceutically acceptable salt thereof.
(21) A compound of any of (1)-(19) wherein T is CONR3R4; or a pharmaceutically acceptable salt thereof.
(22) A compound of any of (1)-(19) wherein T is P(0)(OR5)2; or a pharmaceutically acceptable salt thereof.
(23) A compound of (I) which is elsewhere disclosed herein or is:
Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-
2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } sulfanyl)acetate;
( { 2- [( { 3 - [(4-methoxyphenyl)sulf anyl] -6- [(4-methyl-4H- 1 ,2,4-triazol-3 -yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)acetic acid;
3- [(4-methoxyphenyl)sulfanyl]-N-(5-{ [2-(methylamino)-2-oxoethyl]sulfanyl}-l,3-thiazol-2-yl)- 6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide;
2- ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2-methylpropanoic acid;
Ethyl 3-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } sulfanyl)-2,2-dimethylpropanoate;
3- ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2,2-dimethylpropanoic acid;
Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5-yl}propanoate;
3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l ,3 -thiazol-5 -yl} propanoic acid;
N-[4-(2-Amino-2-oxoethyl)phenyl]-3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4- triazol-3-yl)sulfanyl]pyridine-2-carboxamide;
Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetate yridine-2-carboxamide;
( { 2- [( { 3 - [(4-Methoxyphenyl)sulf anyl] -6-(pyridin-2-ylsulfanyl)pyridin-2-yl } carbonyl) amino] -1,3- thiazol-5-yl}sulfanyl)acetic acid;
Ethyl { 5 -chloro-2- [( { 3 - [(4-methoxyphenyl)sulf anyl] -6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino]-l, 3 -thiazol-4-yl} acetic acid;
Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } propanoate;
3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- 1,3 -thiazol-5 -yl} propanoic acid;
Ethyl {2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-4-yl} acetic acid;
Ethyl ({ 5-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino]thiophen-2-yl } sulfanyl)acetate;
({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } sulfanyl)acetic acid;
Ethyl 3-({ 5-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridin- 2-yl } carbonyl)amino]thiophen-2-yl } sulfanyl)-2,2-dimethylpropanoate;
3-({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2,2-dimethylpropanoic acid;
Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } acetate;
{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl} acetic acid;
Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridi 2-yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetic acid;
Diethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-
2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } methyl)phosphonate;
Ethyl ({ 5-[({ 3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2- yl } sulfanyl)acetate;
({2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5- yl}sulfanyl)acetic acid;
Ethyl { 2-[({ 3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl }carbonyl)amino]-5-chloro- 1 ,3-thiazol- 4-yl} acetate;
{2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-5-chloro-l,3-thiazol-4- yl} acetic acid;
Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetic acid;
Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- 1 ,3-thiazol-4-yl } acetate;
{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-4-yl} acetic acid;
Ethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- 1 ,3 -thiazol-5 -yl } sulfanyl)acetate;
({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl}sulfanyl)acetic acid;
Ethyl 3-({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2,2-dimethylpropanoate;
3- ({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl } sulfanyl)-2,2-dimethylpropanoic acid;
Methyl 3-{2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino]-l ,3-thiazol-5-yl}propanoate;
3-{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl}propanoic acid;
Ethyl (5-chloro-2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetate;
(5-Chloro-2- { [(6- [(4-methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]-3- { [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetic acid; Ethyl [(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)sulfanyl]acetate; [(2-{ [(6-[(4-Methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)sulfanyl]acetic acid;
Diethyl [(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5- yl)methyl]phosphonate;
Ethyl (2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetate;
(2- { [(6- [(4-Methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]-3- { [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetic acid; Methyl 3-(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)propanoate;
3-(2- { [(6- [(4-Methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]-3- { [4- (trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)propanoic acid;
Diethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } methyl)phosphonate;
Ethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } sulfanyl)acetate;
({2-[({3-[(3,4-Dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetic acid;
Ethyl {5-chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l,3-thiazol-4-yl}acetic acid; or
a pharmaceutically acceptable salt thereof.
The present invention also relates to pharmaceutical compositions comprising compounds of any of (l)-(23) and a pharmaceutically acceptable carrier.
Additionally, the present invention relates to use of a compound of any of (l)-(23) in the manufacture of a medicament for use in treating obesity or diabetes.
The present invention relates to the use of a compound of any of (l)-(23) in therapy, for example, in the treatment of diabetes.
The present invention further relates to a method for the treatment of a obesity or diabetes comprising administering to an individual a pharmaceutical composition comprising a compound of any of (l)-(23).
Another embodiment of the present invention includes a method of treating a condition selected from: (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16)
neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, (21) hypertension or other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to treat said condition.
Yet another embodiment of the present invention include a method of treating a condition selected from: (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16)
neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, (21) hypertension or other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient a compound of any of (l)-(23), and a compound from one of the following classes of compounds:
(1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, MK-3102);
(2) insulin sensitizers, including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) PPARa/γ dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those
disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO
2004/020408, and WO 2004/066963); and (4) PPARy partial agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza™, Fortamet™, and GlucophageXR™; and (iii) protein tyrosine phosphatase- IB (PTP-1B) inhibitors (e.g., ISIS-113715 and TTP814);
(3) insulin or insulin analogs (e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro, SBS1000 and oral and inhalable formulations of insulin and insulin analogs);
(4) leptin and leptin derivatives and agonists;
(5) amylin and amylin analogs (e.g., pramlintide);
(6) sulfonylurea and non- sulfonylurea insulin secretagogues (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide);
(7) a-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol);
(8) glucagon receptor antagonists (e.g., NOXG15, LY2409021);
(9) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics; and GLP-1 receptor agonists (e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ΒΓΜ-51077, including intranasal, transdermal, and once-weekly formulations thereof), and oxyntomodulin and oxyntomodulin analogs and derivatives;
(10) LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors
(e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin), (ii) bile acid sequestering agents (e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe), and (iv) acyl CoA:cholesterol acyltransferase inhibitors, (e.g., avasimibe);
(11) HDL-raising drugs, (e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
(12) antiobesity compounds;
(13) agents intended for use in inflammatory conditions, such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
(14) antihypertensive agents, such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), Α-Π receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
(15) other glucokinase activators (GKAs) (e.g., AZD6370);
(16) inhibitors of 11 β-hydroxysteroid dehydrogenase type 1, (e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199);
(17) CETP inhibitors (e.g., anacetrapib, evacetrapib and torcetrapib);
(18) inhibitors of fructose 1,6-bisphosphatase, (e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
(19) inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
(20) AMP-activated Protein Kinase (AMPK) activators, such as MB1055, ETC
1002;
(21) other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
TAK875, CNXOl l, CNX 01162, CNX 01167, JTT 851, SARI, MR 1704, TUG 770, TUG 469, TUG499, ASP 4178);
(22) SSTR3 antagonists (e.g., such as those disclosed in WO 2009/001836);
(23) neuromedin U receptor agonists (e.g., such as those disclosed in WO
2009/042053, including, but not limited to, neuromedin S (NMS));
(24) SCD inhibitors;
(25) GPR-105 antagonists (e.g., such as those disclosed in WO 2009/000087);
(26) SGLT inhibitors (e.g., ASP1941, SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI-10773, ertugliflozin, remogloflozin, TS-071, tofogliflozin, ipragliflozin, and LX-4211);
(27) inhibitors of acyl coenzyme A:diacylglycerol acyltransferase 1 and 2 (DGAT- 1 and DGAT-2);
(28) inhibitors of fatty acid synthase;
(29) inhibitors of acyl coenzyme A:monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2);
(30) agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR);
(31) ileal bile acid transporter inhibitors;
(32) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;
(33) PPAR agonists;
(34) protein tyrosine phosphatase- IB (PTP-1B) inhibitors;
(35) IL-lb antibodies, (e.g., XOMA052 and canakinumab);
(36) bromocriptine mesylate and rapid-release formulations thereof;
(37) GPR 120 agonists (such as KDT501), said compounds being administered to the patient in an amount that is effective to treat said condition.
The invention is further described herein using the terms defined below unless otherwise specified.
"Alkyl", as well as other groups having the prefix "alk", such as alkoxy, and the like, means carbon chains which may be linear or branched, or combinations thereof, containing the indicated number of carbon atoms. If no number is specified, 1-6 carbon atoms are intended for linear and 3-7 carbon atoms for branched alkyl groups. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and the like.
"Alkoxy" refers to an alkyl group linked to oxygen.
"Aryl", alone or in combination, relates to a phenyl, naphthyl or indanyl group. In specific embodiments, the "aryl" is phenyl. The abbreviation "Ph" represents phenyl.
"Cycloalkyl" means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated. If no number of atoms is specified, 3-7 carbon atoms are intended, forming 1-3 carbocyclic rings that are fused. "Cycloalkyl" also includes monocyclic rings fused to an aryl group in which the point of attachment is on the non-aromatic portion. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
tetrahydronaphthyl, decahydronaphthyl, indanyl and the like.
"Heteroaryl" (HAR) unless otherwise specified, means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from oxygen ("O"), sulfur ("S") and nitrogen ("N"). Heteroaryls thus includes heteroaryls fused to other kinds of rings, such as aryls, cycloalkyls and heterocycles that are not aromatic. Examples of heteroaryl groups include: pyrrolyl or pyrrole, isoxazolyl or isoxazole, isothiazolyl or isothiazole, pyrazolyl or pyrazole, pyridyl, oxazolyl or oxazole, oxadiazolyl or oxadiazole, thiadiazolyl or thiadiazole, thiazolyl or thiazole, imidazolyl or imidazole, triazolyl or triazole, tetrazolyl or tetrazole, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl or benzisoxazole, benzoxazolyl or benzoazole, benzothiazolyl or benzothiazole, benzothiadiazolyl or benzothiadiazole, dihydrobenzofuranyl or
dihydrobenzofurane, indolinyl or indoline, pyridazinyl or pyridazine, indazolyl or indazole, isoindolyl or isoindole, dihydrobenzothienyl, indolizinyl or indolizine, cinnolinyl or cinnoline, phthalazinyl or phthalazine, quinazolinyl or quinazoline, naphthyridinyl or naphthyridine, carbazolyl or carbazole, benzodioxolyl or benzodioxole, quinoxalinyl or quinoxaline, purinyl or purine, furazanyl or furazane, isobenzylfuranyl or isobenzylfurane, benzimidazolyl or benzimidazole, benzofuranyl or benzofurane, benzothienyl or benzothiene, quinolyl or quinoline, oxo-dihydroqunoline, indolyl or indole, oxindole, isoquinolyl or isoquinoline, dibenzofuranyl or dibenzofurane, and the like. For heterocyclic and heteroaryl groups, rings and ring systems containing from 5-15 atoms are included, forming 1-3 rings.
"Heterocycle" or "heterocyclic" refers to nonaromatic cyclic ring structures in which one or more atoms in the ring, the heteroatom(s), is an element other than carbon.
Heteroatoms are typically O, S or N atoms.
"Halogen" (Halo) includes fluorine, chlorine, bromine and iodine.
Unless expressly depicted or described otherwise, variables depicted in a structural formula with a "floating" bond, such as substituent -L-T, are permitted on any available carbon atom in the ring to which each is attached.
Substitution, where applicable, may be on any available carbon atom that results in a stable structure. Furthermore, where language indicates that certain groups or substituents are further optionally substituted, that language includes all groups or substituents having that feature. For example, use of the language "wherein the alkyl, alkoxy, NR3R4 or S(0)o-2 substituents are further optionally substituted" indicates that any substituents possessing an alkyl, alkoxy, NR3R4 or S(0)o-2 component can be substituted within that component.
Also, number ranges where provided (e.g., 1-4, 0-3, etc.) expressly include each and every number in that range as a discrete embodiment.
Atoms of the compounds described herein may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of any of (l)-(23). For example, different isotopic forms of hydrogen (H) include protium (IK) and deuterium (¾T). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may yield certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
Isotopically-enriched compounds of any of (l)-(23) described herein can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
Individual tautomers of the compounds of any of (l)-(23), as well as mixtures thereof, are encompassed herein. Tautomers are defined as compounds that undergo rapid proton shifts from one atom of the compound to another atom of the compound. Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form known as keto-enol tautomers.
Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers. When bonds to the chiral carbon are depicted as straight lines in the formulas of the invention, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the compounds of (l)-(23). The present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers. Except where otherwise specified, the formulae
encompassing compounds of the present invention are shown without a definitive
stereochemistry at certain positions. The present invention therefore may be understood to include all stereoisomers of compounds of any of (l)-(23) and pharmaceutically acceptable salts thereof.
It is generally preferable to administer compounds of the present invention as enantiomerically pure formulations. Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral
chromatography, derivatization with a chiral auxiliary followed by separation by
chromatography or crystallization, and fractional crystallization of diastereomeric salts.
Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column.
Further, any enantiomer or diastereomer of a compound of any of (l)-(23) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Solvates, and in particular, the hydrates of the compounds of any of (l)-(23) are also included in the present invention.
Of import, the disclosed compounds have glucokinase activation activity, and therefore they are useful as therapeutic agents and/or preventive agents for diabetes mellitus as well as for diabetic complication.
Diabetic complication means diseases caused by development of diabetes mellitus and includes, for example, diabetic nephropathy, diabetic retinopathy, diabetic neurosis, diabetic arteriosclerosis, and so on.
The compounds of the present invention are considered of potential utility in the treatment of both insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM).
Insulin dependent diabetes mellitus (IDDM) is a "multi-factorial autoimmune disease for which susceptibility is determined by environmental and genetic factors"; see Tisch, R. and McDevitt, H. (1996) Cell 85. 291-297. Insulin dependent diabetes mellitus is classified as type I and type II depending on the predisposition.
In type II diabetes mellitus, the blood sugar after meals is markedly maintained at a high level for a long period of time in comparison with that of healthy persons.
Compounds disclosed herein may be used in the manufacture of medicaments for treating one or more of the following diseases or conditions, including, without limitation:
(1) noninsulin dependent diabetes mellitus (type 2 diabetes);
(2) hyperglycemia;
(3) metabolic syndrome/ syndrome X;
(4) obesity;
(5) ischemia and myocardial infarction;
(6) neurological disorders such as Alzheimer's disease, schizophrenia, and impaired cognition;
(5) hypercholesterolemia;
(6) hypertriglyceridemia (elevated levels of triglyceride-rich-lipoproteins);
(7) mixed or diabetic dyslipidemia;
(8) low HDL cholesterol;
(9) high LDL cholesterol;
(10) hyperapobetalipoproteinemia; and
(11) atherosclerosis.
The present invention also relates to a method for the treatment and control of mixed or diabetic dyslipidemia, hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, and/or hypertriglyceridemia, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of any of (1)- (23) or a pharmaceutically acceptable salt thereof. The compound may be used alone or advantageously may be administered with a cholesterol biosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor (e.g., simvastatin, atorvastatin, and the like). The compound may also be used advantageously in combination with other lipid lowering drugs such as cholesterol absorption inhibitors (e.g., stanol esters, sterol glycosides or azetidinones such as ezetimibe), ACAT inhibitors (e.g., avasimibe), CETP inhibitors (e.g. anacetrapib), niacin, bile acid sequestrants, microsomal triglyceride transport inhibitors, and bile acid reuptake inhibitors. Such combination treatments are useful for the treatment or control of conditions such as
hypercholesterolemia, atherosclerosis, hyperlipidemia, hypertriglyceridemia, dyslipidemia, high LDL, and low HDL.
Another aspect of the invention provides a method for the treatment and control of obesity or metabolic syndrome, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of (l)-(23). The compound may be used alone or advantageously may be administered with an anti-obesity agent, such as a lipase inhibitor (e.g., orlistat,) or a monoamine neurotransmitter uptake inhibitor (e.g., sibutramine or phentermine). The compound may also be used advantageously in combination with CB-1 inverse agonists or antagonists (e.g., rimonabant or taranabant).
The present invention further relates to a method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient a compound of any of (l)-(23) in an amount that is effective to treat hyperglycemia, diabetes or insulin resistance.
Yet another aspect of the invention that is of interest relates to a method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound of any of (l)-(23) in an amount that is effective to treat atherosclerosis.
Yet another aspect of the invention that is of interest relates to a method of delaying the onset of one of the aforementioned conditions and disorders where insulin resistance is a component in a mammalian patient in need thereof, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to delay the onset of said condition.
Yet another aspect of the invention that is of interest relates to a method of reducing the risk of developing one of the aforementioned conditions and disorders where insulin resistance is a component in a mammalian patient in need thereof, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to reduce the risk of developing said condition.
Yet another aspect of the invention that is of interest relates to a method of treating a condition or reducing the risk of developing a condition or delaying the onset of a condition selected from the group consisting of (1) hyperglycemia, (2) impaired glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, (21) hypertension and other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient a compound of any of (l)-(23) in an amount that is effective to treat said condition, and a compound selected from the group consisting of:
(1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, omarigliptin);
(2) insulin sensitizers, including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) PPARa/γ dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO
2004/020408, and WO 2004/066963); and (4) PPARy partial agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza™, Fortamet™, and GlucophageXR™; and (iii) protein tyrosine phosphatase- IB (PTP-1B) inhibitors (e.g., ISIS-113715 and TTP814);
(3) insulin or insulin analogs (e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro, SBS1000 and oral and inhalable formulations of insulin and insulin analogs);
(4) leptin and leptin derivatives and agonists;
(5) amylin and amylin analogs (e.g., pramlintide);
(6) sulfonylurea and non- sulfonylurea insulin secretagogues (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide);
(7) a-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol);
(8) glucagon receptor antagonists (e.g., NOXG15, LY2409021);
(9) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics; and GLP-1 receptor agonists (e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and ΒΓΜ-51077, including intranasal, transdermal, and once-weekly formulations thereof), and oxyntomodulin and oxyntomodulin analogs and derivatives;
(10) LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors
(e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin), (ii) bile acid sequestering agents (e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe), and (iv) acyl CoA:cholesterol acyltransferase inhibitors, (e.g., avasimibe);
(11) HDL-raising drugs, (e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
(12) antiobesity compounds;
(13) agents intended for use in inflammatory conditions, such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
(14) antihypertensive agents, such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), Α-Π receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
(15) other glucokinase activators (GKAs) (e.g., AZD6370);
(16) inhibitors of 11 β-hydroxysteroid dehydrogenase type 1, (e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199);
(17) CETP inhibitors (e.g., anacetrapib, evacetrapib and torcetrapib);
(18) inhibitors of fructose 1,6-bisphosphatase, (e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
(19) inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
(20) AMP-activated Protein Kinase (AMPK) activators, such as MB1055, ETC
1002;
(21) other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
TAK875, CNXOl l, CNX 01162, CNX 01167, JTT 851, SARI, MR 1704, TUG 770, TUG 469, TUG499, ASP 4178);
(22) SSTR3 antagonists (e.g., such as those disclosed in WO 2009/001836);
(23) neuromedin U receptor agonists (e.g., such as those disclosed in WO
2009/042053, including, but not limited to, neuromedin S (NMS));
(24) SCD inhibitors;
(25) GPR-105 antagonists (e.g., such as those disclosed in WO 2009/000087);
(26) SGLT inhibitors (e.g., ASP1941, SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI-10773, ertugliflozin, remogloflozin, TS-071, tofogliflozin, ipragliflozin, and LX-4211);
(27) inhibitors of acyl coenzyme A:diacylglycerol acyltransferase 1 and 2 (DGAT- 1 and DGAT-2);
(28) inhibitors of fatty acid synthase;
(29) inhibitors of acyl coenzyme A:monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2);
(30) agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR);
(31) ileal bile acid transporter inhibitors;
(32) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;
(33) PPAR agonists;
(34) protein tyrosine phosphatase- IB (PTP-1B) inhibitors;
(35) IL-lb antibodies, (e.g., XOMA052 and canakinumab);
(36) bromocriptine mesylate and rapid-release formulations thereof;
(37) GPR 120 agonists (such as KDT501); said compounds being administered to the patient in an amount that is effective to treat said condition.
For dosing purposes, any suitable route of administration may be employed for providing a mammal, especially a human, with an effective amount of a compound of the present invention. Dosage forms may include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Most preferably, compounds of any of (1)- (23) are administered orally. The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
When treating or controlling diabetes mellitus or other diseases for which compounds of any of (l)-(23) are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1.0 milligrams to about 1000 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 1 milligram to about 350 milligrams. For a particularly potent compound, the dosage for an adult human may be as low as 0.1 mg. The dosage regimen may be adjusted within this range or even outside of this range to provide the optimal therapeutic response. Oral administration will usually be carried out using tablets or capsules. Examples of doses in tablets and capsules are 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 25 mg, 50 mg, 100 mg, 200 mg, 350 mg, 500 mg, 700 mg, 750 mg, 800 mg and 1000 mg. Other oral forms may also have the same or similar dosages.
Another aspect of the invention that is of interest is a pharmaceutical composition comprised of a compound of any of (l)-(23) in combination with a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention comprise a compound of any of (l)-(23) as an active ingredient, as well as a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
Salts of basic compounds encompassed within the term "pharmaceutically acceptable salt" refer to non-toxic salts of the compounds described herein which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds described herein include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, edetate, edisylate, estolate, esylate, formate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride,
hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N- methylglucamine ammonium salt, oleate, oxalate, palmitate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Furthermore, where the compounds described herein carry an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
A pharmaceutical composition may also comprise a prodrug, or a pharmaceutically acceptable salt thereof, if a prodrug is administered.
The compositions are typically suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the particular active ingredient selected. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art.
In practical use, compounds of any of (l)-(23) can be combined as the active ingredient in intimate admixture with the pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral
(including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid
preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage form. Solid pharmaceutical carriers are therefore typically employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations typically comprise at least about 0.1 percent of active compound, the remainder of the composition being the carrier. The percentage of active compound in these compositions may, of course, be varied and is conveniently between about 2 percent to about 60 percent of the weight of the dosage form. The amount of active compound in such
therapeutically useful compositions is such that an effective dosage will be delivered.
Alternatively, the active compound can be administered intranasally as, for example, in the form of liquid drops or a spray.
The tablets, capsules and the like also typically contain a binder. Examples of suitable binders include gum tragacanth, acacia, gelatin and a synthetic or semisynthetic starch derivative, such as hydroxypropylmethylcellulose (HPMC); excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and in some instances, a sweetening agent such as sucrose, lactose or saccharin. When the dosage form employed is a capsule, it may contain, in addition to the components described above, a liquid carrier such as fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. Syrups and elixirs typically contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl or propylparabens as a preservative, a dye and a flavoring such as cherry or orange flavor.
The compounds of any of (l)-(23) may also be administered parenterally.
Solutions or suspensions of these active compounds can be prepared in water, saline or another biocompatible vehicle, suitably mixed with a surfactant, buffer, and the like. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in an oil. Under ordinary conditions of storage and use, these preparations can also contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions and dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions and dispersions. The preparation should be prepared under sterile conditions and be fluid to the extent that easy syringability exists. It should be sufficiently stable under the conditions of manufacture and storage and preserved against the growth of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and suitable oils.
As discussed supra, compounds of the present invention may be used in combination with other drugs that may also be useful in the treatment or amelioration of the individual diseases and conditions described herein. Such other drugs may be administered by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of any of (l)-(23). In the treatment of patients who have type 2 diabetes, insulin resistance, obesity, metabolic syndrome, neurological disorders, and co-morbidities that accompany these diseases, more than one drug is commonly administered. The compounds of this invention may generally be administered to a patient who is already taking one or more other drugs for these conditions.
When a compound of any of (l)-(23) is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of any of (l)-(23) is preferred. However, the combination therapy also includes therapies in which a compound of any of (l)-(23) and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compound of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of any of (l)-(23).
Examples of other active ingredients that may be administered separately or in the same pharmaceutical composition in combination with a compound of any of (l)-(23) include, but are not limited to:
(1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, alogliptin, linagliptin, vildagliptin, saxagliptin, teneligliptin, MK-3102);
(2) insulin sensitizers, including (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, PPARa/γ aleglitazar, sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM's), (e.g., such as those disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO partial 2004/020409, WO 2004/020408, and WO 2004/066963); and (4) PPARy agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza™, Fortamet™, and GlucophageXR™; and (iii) protein tyrosine phosphatase- IB (PTP-IB) inhibitors (e.g., ISIS-113715 and TTP814);
(3) insulin or insulin analogs (e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro, SBS1000 and oral and inhalable formulations of insulin and insulin analogs);
(4) leptin and leptin derivatives and agonists;
(5) amylin and amylin analogs (e.g., pramlintide);
(6) sulfonylurea and non- sulfonylurea insulin secretagogues (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide);
(7) a-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol); (8) glucagon receptor antagonists (e.g., NOXG15, LY2409021);
(9) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics; and GLP-1 receptor agonists (e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, GSK2374697, ADX72231, RG7685, NN9924, ZYOG1, CJC-1131, and BIM-51077, including intranasal, transdermal, and once-weekly formulations thereof), and oxyntomodulin and oxyntomodulin analogs and derivatives;
(10) LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin), (ii) bile acid sequestering agents (e.g., colestilan, colestimide, colesevalam
hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe), and (iv) acyl CoA:cholesterol acyltransferase inhibitors, (e.g., avasimibe);
(11) HDL-raising drugs, (e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524);
(12) antiobesity compounds;
(13) agents intended for use in inflammatory conditions, such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors;
(14) antihypertensive agents, such as ACE inhibitors (e.g.,lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril), Α-Π receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (e.g., aliskiren), beta blockers, and calcium channel blockers;
(15) other glucokinase activators (GKAs) (e.g., AZD6370);
(16) inhibitors of 11 β-hydroxysteroid dehydrogenase type 1, (e.g., such as those disclosed in U.S. Patent No. 6,730,690, and LY-2523199);
(17) CETP inhibitors (e.g., anacetrapib, evacetrapib and torcetrapib);
(18) inhibitors of fructose 1,6-bisphosphatase, (e.g., such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476);
(19) inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2);
(20) AMP-activated Protein Kinase (AMPK) activators, such as MB1055, ETC
1002;
(21) other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, APD597, GSK1292263, HM47000, and PSN821), and (iii) GPR-40 (e.g.,
TAK875, CNX011, CNX 01162, CNX 01167, JTT 851, SARI, MR 1704, TUG 770, TUG 469, TUG499, ASP 4178);
(22) SSTR3 antagonists (e.g., such as those disclosed in WO 2009/001836);
(23) neuromedin U receptor agonists (e.g., such as those disclosed in WO
2009/042053, including, but not limited to, neuromedin S (NMS));
(24) SCD inhibitors;
(25) GPR-105 antagonists (e.g., such as those disclosed in WO 2009/000087);
(26) SGLT inhibitors (e.g., ASP1941 , SGLT-3, empagliflozin, dapagliflozin, canagliflozin, BI- 10773, ertugliflozin, remogloflozin, TS-071 , tofogliflozin, ipragliflozin, and LX-421 1);
(27) inhibitors of acyl coenzyme A:diacylglycerol acyltransferase 1 and 2 (DGAT- 1 and DGAT-2);
(28) inhibitors of fatty acid synthase;
(29) inhibitors of acyl coenzyme A:monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2);
(30) agonists of the TGR5 receptor (also known as GPBAR1 , BG37, GPCR19, GPR131 , and M-BAR);
(31) ileal bile acid transporter inhibitors;
(32) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;
(33) PPAR agonists;
(34) protein tyrosine phosphatase- IB (PTP- 1B) inhibitors;
(35) IL- lb antibodies, (e.g., XOMA052 and canakinumab);
(36) bromocriptine mesylate and rapid-release formulations thereof; or
(37) GPR 120 agonists (such as KDT501).
Another aspect of the invention that is of interest relates to the use of a compound of any of (l)-(23) in the manufacture of a medicament for use in treating a disease or condition described herein.
The glucokinase-activating capability of the compounds (I) may be determined according to methods previously described (e.g., Diabetes, 45, 1671- 1677, 1996).
The glucokinase activity can, for instance, be determined without directly measuring glucose-6-phosphate by measuring the amount of Thio-NADH generated during the production of phosphogluconolactone from glucose-6-phosphate by a reporter enzyme glucose-6- phosphate dehydrogenase.
To test the exemplified compounds, the following assay was employed.
Recombinant human liver glucokinase was expressed as a FLAG fusion protein in E.coli, and purified on ANTIFLAG M2 AFFINITY GEL (Sigma). The assay was carried out at 30°C in a 96-well plate. In the plate was distributed 69μ1 each of assay buffer (25 mM Hepes Buffer: pH=7.2, 2 mM MgCl2, 1 mM ATP, 0.5 mM TNAD, 1 mM dithiothreitol), to which was added Ι μΐ of a DMSO solution of the compound or DMSO as control. Then, 20μ1 of pre-ice-cooled enzyme mixture (FLAG-GK, 20U/ml G6PDH) was distributed thereto, to which was added ΙΟμΙ
of 25 mM glucose as substrate to initiate the reaction (final glucose concentration = 2.5 mM). After starting the reaction, the absorbance at 405 nm was measured every 30 seconds for 10 minutes to evaluate the compound based on the initial increase for 5 minutes. FLAG-GK was added so that the increase of absorbance after 5 minutes fell between 0.05 to 0.1 in the presence of l DMSO.
The OD values of the respective compounds were measured in the respective concentrations, wherein the OD value of DMSO as control is regarded as 100%. From the OD values at the respective concentrations, Emax (%, 2.5 mM Glu) and EC50 (nM, 2.5 mM Glu) were calculated and used as indicators of the GK activation capability of the compounds.
According to the above assay, the GK activation capability of the exemplified compounds of the present invention was determined. The following table shows the results.
Table
As shown in the table, the compounds of the present invention have sufficient GK activation capability when Emax and EC50 are employed as indicators. Furthermore, the disclosed and exemplified compounds have the potential to be more liver-preferring over the pancreas, enabling the disclosed and exemplified compounds to potentially reduce the risk of hypoglycemia in individuals being treated.
The compounds of the invention can be prepared using the synthetic schemes described herein as well as any of several alternate methods which will be apparent to a chemist skilled in the art. The following abbreviations may be used in the synthetic schemes or
Examples: AcCl is acetyl chloride; DCM is dichloromethane; DIEA is N,N- Diisopropylethylamine; DMA is dimethylacetamide; DMAP is dimethylaminopyridine; DMF is N,N-dimethylformamide; DMI is 1.3-dimethyl-2-Imidazolidinone; DMSO is dimethyl sulfoxide; DTT is dithiothreitol; EDC or EDCI is l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide HC1; EtOAc is ethyl acetate; EtOH is ethanol; h is hours; HC1 is hydrochloric acid; HOBt is 1- hydroxybenzotriazole; HPLC is high performance liquid chromatography; LAH is lithium aluminum hydride; M is molar; min is minutes; mmol is millimole; NCS is N-chlorosuccinimide; rt or RT is room temperature; SM is starting material; TEA is triethylamine; TFA is
trifluoroacetic acid; THF is tetrahydrofuran; TLC is thin layer chromatography; and TNAD is thionicotinaniide-adenine dinucleotide.
GENERAL SCHEMES
Certain compounds of formula I in the invention may be prepared starting from the compound of formula VII by Method A as shown in the following Reaction Scheme. A person of skilled in the art will understand that additional methods may also be used. A person skilled in the art will appreciate that alternative reagents, temperatures and solvents may be used to effect the same transformation. In other words, the compounds of the invention can be made using organic synthesis using starting materials, reagents and reactions well known in the art.
wherein Xi and X2 are functional groups that will be converted into aryl- or heteroaryl-thio groups, preferably chloro or fluoro;
R1, R2, R3, R 4, L, T and X are as above.
Step 1
The carboxylic acids of formula VII wherein Xi and X2 are both chloro is commercially available. The carboxylic acids of formula VII wherein Xi is fluoro and X2 is chloro is also commercially available. The carboxylic acids can be converted to the
corresponding ieri-butyl esters of formula VI using any conventional esterification methods.
Thus resulting compound VI may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
Step 2
In this step, the Xi group of formula VI can be displaced by an arylthio group in the presence of a base, such as potassium carbonate and cesium carbonate, in a polar solvent, such as DMF, at ambient temperature or a slightly higher temperature.
Thus resulting compound V may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
Step 3
In this step, the X2 group of formula V can be displaced by an arylthio or heteroaryl thio group in the presence of a base, such as potassium tert-butoxide, potassium carbonate and cesium carbonate, in a polar solvent, such as DMF and DMA, usually at higher temperature.
Thus resulting compound IV may be isolated and purified by conventional means, for example, concentration extraction, vacuum condensation, chromatography, and so on.
Step 4
In this step, the ieri-butyl ester prepared from Step 3 can be converted to the corresponding carboxylic acid by the treatment of a strong acid, such as TFA, HC1 and so on.
Thus resulting compound III may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
Alternatively, the compound III may be used in the subsequent step without purification.
Step 5
In this step, acid III is allowed to react with the amino compound (II) to give compound I. The reaction may be carried by performing amide-formation reactions by a method as described previously (for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
Thus resulting compound I may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
Step 6
In this step, compound I wherein T is an carboxylic ester group may be saponified by the treatment of a base followed by acidification to give the corresponding carboxylic acid 1-1. The base used in this step may be alkali hydroxides, such as lithium hydroxide and sodium hydroxide.
Thus resulting compound 1-1 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
Step 7
In this step, carboxylic acid 1-1 is allowed to reacted with an amine to give the corresponding carboxamde. The reaction may be carried by performing amide-formation reactions by a method as described previously for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
Thus resulting compound 1-2 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
Step 8
In this step, compound I wherein T is an carboxylic ester group may be transformed into the corresponding carboxamide 1-2 by heating with an amine or by the reaction with an amine in the presence of a Lewis acid, such as trimethylaluminum, etc, with or without heating.
Thus resulting compound 1-2 may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on. Alternatively, certain compounds of formula I in the invention may be prepared starting from the compound of formula X by Method B as shown in the following Reaction Scheme.
M
VIII
Step 1
In this step, acid X is allowed to react with the amino compound (II) to give compound IX. The reaction may be carried by performing amide-formation reactions by a method as described previously (for example, Comprehensive Organic Synthesis, 6, Pergamon Press, 1991), by a method according thereto, or by a combination of these and ordinary methods.
Thus resulting compound IX may be isolated and purified by conventional means, for example, concentration, extraction, vacuum condensation, chromatography, and so on.
Step 2
In this step, the Xi group of formula IX can be displaced by an arylthio group in the presence of a base, such as potassium carbonate and cesium carbonate, in a polar solvent, such as DMF, at ambient temperature or a slightly higher temperature.
Thus resulting compound VIII may be isolated and purified by conventional means, for example, extraction, vacuum condensation, chromatography, and so on.
Step 3
In this step, the X2 group of formula VIII can be displaced by an arylthio or heteroaryl thio group in the presence of a base, such as potassium tert-butoxide, potassium carbonate and cesium carbonate, in a polar solvent, such as DMF and DMA, usually at higher temperature.
Thus resulting compound I may be isolated and purified by conventional means, for example, concentration extraction, vacuum condensation, chromatography, and so on.
INTERMEDIATES
Preparation of ethyl [(2-amino-l,3-thiazol-5-yl)sulfanyl]acetate
M K2C03
H3N' Br HS C02Et h N C02Et Br DMF, rt
A flask charged with a magnetic stirring bar, 5-bromo-2-aminothiazole hydrobromide salt (3.00 g, 11.54 mmol), potassium carbonate (4.78 g, 34.60 mmol) and anhydrous DMF (10 mL) was purged with nitrogen and cooled in an ice- water bath. To the stirring suspension was added ethyl thioglycolate (1.387 g, 11.54 mmol). The mixture was
allowed to warm to rt and stirred for 16 h. It was diluted with ethyl acetate (50 mL) and washed with water (50 mL). The aqueous layer was extracted with ethyl actate (50 mL). The combined organic layers were washed with water (50 mL x 2) and brine (50 mL). The organic layer was separated and dried over sodium sulfate. After filtration and concentration, the crude product was purified by flash column chromatography (Biotage Flash 40M) gradually eluting with 30-100% ethyl acetate in hexane (with 2% TEA) to afford ethyl [(2-amino-l,3-thiazol-5-yl)sulfanyl]acetate as a yellow oil (1.72 g, 68%), which solidified after refrigeration.
Preparation of ethyl 2-[(2-amino-l,3-thiazol-5-yl)sulfanyl]-2-methylpropanoate
A solution of 2-aminothiazole (3.5 g, 35 mmol) and sodium thiocyanate (8.9 g, 110 mmol) in methanol (40 mL) was stirred in an ice-acetone bath (-10 °C) for 5 min. A solution of bromine (1.8 mL, 34.9 mmol) in methanol (10 mL) saturated with sodium bromide was added dropwise by a glass pipette over 20 min keeping the internal temperature between -5 to 0 °C. Some off-white precipitations were formed at the end of addition. The suspension was stirred at 0 °C for another 30 min, and then it was kept in a refrigerator overnight. The mixture was stirred at 0 °C for 2.5 h before it was poured into 150 mL ice-water. The suspension was stirred for 10 min and precipitations were collected by filtration followed by rinsing with ice- water (10 mL) three times. The yellow solid was dried at 60 °C under vacuum for 1 h to afford 2-amino-l ,3-thiazol- 5-yl thiocyanate (1.58 g, 29%).
In a 50 mL flask was charged with a stirring bar, DTT (491 mg, 3.18 mmol) and 2-amino-5-thiocyanato-thiazole (500 mg, 3.18 mmol). The flask was sealed and purged with nitrogen. Methanol (15 mL) was added to it and the mixture was stirred at room temperature for 1.5 h. Potassium carbonate (527 mg, 3.82 mmol) and ethyl 2-bromoisobutyrate (682, 3.50 mmol) were added to the reaction and stirred under nitrogen overnight. Most of the solvent was evaporated and the residue was partitioned between water and ethyl acetate. The organic layer was washed once with water and then brine. It was separated and dried over sodium sulfate. After concentration in vacuo the residue was purified by flash column chromatography eluting with 1 : 1
ethyl acetate:hexane. The fractions were combined and concentrated. The residue was dissolved in diethyl ether and washed with water three times. The organic layer was dried over sodium sulfate and concentrated to afford the title compound as a yellow oil (423 mg, 54%). Preparation of ethyl 3-[(2-amino-l,3-thiazol-5-yl)sulfanyl]-2,2-dimethylpropanoate
The solution of 5-thiocyanato-thiazol-2-ylamine (4.00 g, 25.4 mmol) in methanol (100 mL, degassed by bubbling nitrogen for 15 min) was added sodium borohydride (1.155 g, 30.5 mmol) in one portion. The reaction was stirred for 30 min under nitrogen and was added 3- bromo-2,2-dimethyl-propionic acid (6.91 g, 38.2 mmol) in one portion followed by
diisopropylethylamine (4.54 mL, 25.4 mmol). The reaction was stirred overnight at rt. It was added about 150 mL of 5% citric acid to adjust the pH to 4. Most organic solvent was removed and the mixture was extracted with 2: 1 chloroform:2-propanol four times. The combined organic layers were dried over sodium sulfate and concentrated to give brown glue-like crude product
(8.7 g).
Acetyl chloride (5.45 mL, 76.0 mmol) was added slowly to anhydrous ethanol (70 mL) with stirring at 0 °C to generate a solution of HCl in ethanol. The solution was added to a solution of the crude product above in ethanol (30 mL) and stirred for 18 h at 50 °C. Most solvent was removed in vacuo and the residue was purified by flash column chromatography to give the title compound as a brown solid (4.58 g, 69%).
Preparation of 5-(3-methoxy-3-oxopropyl)-l,3-thiazol-2-aminium bromide
Methyl 5-bromo-4-oxopentanoate (prepared by a literature procedure: Synthesis 2007, 23, 3731-3735) (3.64 g, 17.41 mmol) and thiourea (1.326 g, 17.41 mmol) in ethanol were
heated to reflux overnight. The reaction mixture was cooled to room temperature and the white crystals were filtrated and washed with cool ethanol (5 mL x 2), ethyl acetate (10 mL) and diethyl ether (20 mL) in the order given. They were collected and dried under vacuum to give 4.2 g of 5- (3-ethoxy-3-oxopropyl)-l ,3-thiazol-2-aminium bromide as pink solids (90%). (ES+) parent m/z: 187.18 (M+H)+.
J acidic acid H2N Λ
Ethyl 2-aminothiazole-4-acetate (5.48 g, 29.4 mmol) in acetic acid (300 ml) was added NCS (4.32 g, 32.4 mmol) at room temperature. The reaction was stirred for 2 h and it was concentrated to give a red residue. Solids were formed and the mixture was suspended in acetone/diethyl ether (1/1, 20 mL) stirring overnight. The solids were filtrated and washed with acetone/diethyl ether (1/1, 50 mL) in several portions to give ethyl 2-amino-5-chlorothiazole-4- acetate (3.24 g, 14.68 mmol, 49.9 % yield) as a brick-red solid.
O, o.
BocHN s ci (Eto)3P BocHN s 0Et TFA ^ ^"00
- I ^ I ^oa N^ 0H
Ethyl 2-amino-l ,3-thiazole-5-carboxylate (4.33 g, 25.1 mmol), (Boc)20 (6.13 ml, 26.4 mmol) and DMAP (0.061 g, 0.503 mmol) in THF (50 ml) was stirred overnight. White solids were form, which can barely be dissolved in DMSO or methanol but not in most organic solvent and water. It was filtrated and washed with ethyl acetate, dried under high vacuum to give ethyl 2-[(ieri-butoxycarbonyl)amino]-l,3-thiazole-5-carboxylate (5.46 g, 20.12 mmol, 80 % yield) as a pale white solid, m/z: 271.10 [M-l]~.
To a clean dry 500 mL flask was charged with a magnetic stirring bar, ethyl 2- [(ieri-butoxycarbonyl)amino]-l ,3-thiazole-5-carboxylate (5.46 g, 20.12 mmol) and anhydrous THF (100 ml). The solution was cooled to 0 °C by an ice-bath and was slowly added 1 M L1AIH4 in diethyl ether (24.15 ml, 24.15 mmol) over 5 min. The mixture was stirred for 20 min and the ice-bath was removed to allow the reaction warmed to room temperature, stirring for another 2 h. It was cooled to 0 oC and quenched carefully with water (1 mL), then 15% NaOH (3 mL). The mixture was stirred vigorously for 2 h. The white solids were removed by filtration through Celite. To the filtrate was added about 15 g of silica gel and it was concentrated in vacuo. The silica gel was dried and loaded on a Biotage column and eluted with 0-100% ethyl acetate to give ieri-butyl [5-(hydroxymethyl)-l ,3-thiazol-2-yl]carbamate (2.9 g, 12.59 mmol, 62.6 % yield) as a white solid. 'H-NMR (500 MHz, DMSO- ): δ (ppm) = 11.28 (s, 1H), 7.18 (s, 1H), 5.32 (t, / = 6 Hz, 2H), 4.55 (d, / = 6 Hz, 1H), 1.49 (s, 9H). (ES+) m/z: 230.92 (M+H)+.
Thionyl chloride (3.68 ml, 50.4 mmol) was added to the suspension of ieri-butyl [5-(hydroxymethyl)-l ,3-thiazol-2-yl]carbamate (2.9 g, 12.59 mmol) in DCM (10 ml) at 0 OQ The reaction was stirred for 1 h, then it was concentrated in vacuo. The residue was used in the next step without further purification. 'H-NMR (500 MHz, DMSO-i¾): δ (ppm) = 7.41 (s, 1H), 5.01 (t, / = 6 Hz, 2H), 1.50 (s, 9H). To a 250 mL of flask was charged a magnetic stirring bar, ieri-butyl [5-
(chloromethyl)-l,3-thiazol-2-yl]carbamate (3.13 g, 12.58 mmol) , anhdrous THF (60 ml) and triethyl phosphite (17.52 ml, 101 mmol). The reaction mixture was heated to reflux overnight. Cooled to rt. Concentrated and purified by Biotage (Flash 40M, 0-100% ethyl acetate in hexane) to give diethyl ({2-[(ieri-butoxycarbonyl)amino]-l,3-thiazol-5-yl}methyl)phosphonate (4.28 g, 12.22 mmol, 97 % yield) as a colorless oil. (ES+) m/z: 350.18 (M+H)+.
A solution of diethyl ({2-[(ieri-butoxycarbonyl)amino]-l ,3-thiazol-5- yl}methyl)phosphonate (4.23 g, 12.07 mmol) in DCM (45 ml) was added TFA (25 ml, 324 mmol) and stirred for 2 h at rt. It was concentrated and diluted with DCM, washed with sodium bicarbonate and then brine. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by Biotage (Flash 40 M, 0-8% methanol in DCM) to give diethyl [(2- amino-l ,3-thiazol-5-yl)methyl]phosphonate (1.35 g, 5.39 mmol, 44.7 % yield) as white crystals. (ES+) m/z: 250.96 (M+H)+.
EXAMPLES
Example 1
Ethyl (|2-r(| 3-r(4-methoxyphenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridin- 2-yl ] carbonvDaminol - 1 ,3 -thiazol- -yl ] sulfanvDacetate
Method A
Step 1
The suspension of 6-chloro-3-fluoropyridine-2-carboxylic acid (3.51 g, 20.0 mmol) and ieri-butyl 2,2,2-trichloroacetimidate (7.16 mL, 40.0 mmol) in anhydrous DCM (80 mL) was added BF3 etherate (0.507 mL, 4.0 mmol) at ambient temperature. After stirred vigorously for 36 h, The suspension was diluted with diethyl ether and washed with sodium carbonate (100 mL x 2) and brine (100 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography (Biotage Flash 40 M) eluting gradually with 10-50% ethyl acetate to afford the title compound as a colorless oil (3.27 g, 71 %).
Step 2
Preparation of ieri-butyl 6-chloro-3-[(4-methoxyphenyl)sulfanyl]pyridine-2-carboxylate
ieri-Butyl 6-chloro-3-fluoropyridine-2-carboxylate (3.20 g, 13.81 mmol), potassim carbonate (2.10 g, 15.20 mmol), and 4-methoxythiophenol (1.937 g, 13.81 mmol) were stirred in anhydrous DMF (40 mL) at ambient temperature for 12 h. The mixture was diluted with water (50 mL) and extracted with ethyl acetate three times (50 mL x 3). The combined organic layers were washed with water three times (20 mL x 3), then with brine once. The organic layer was separated, dried over sodium sulfate, filtrated and concentrated in vacuo. The residue was purified by Biotage (Flash 40M) gradually eluted with 10-40% EtOAc/Hexane to afford the title compound as white crystals (3.63 g, 75%). 'HNMR (500 MHz, CDC13) δ (ppm) = 7.49 (dd, / = 6.6, 2.1 Hz, 2H), 7.15 (d, / = 8.5 Hz, 1H), 7.08 (d, / = 8.6 Hz, 1H), 7.00 (dd, / = 6.7, 2.1 Hz, 2H), 3.89 (s, 3H), 1.71 (s, 9H).
Step 3
Preparation of ieri-butyl 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylate
To a clean dry 50 mL flask was charged with a magnetic stirring bar and potassium ieri-butoxide (0.58 g, 5.17 mmol) and 4-methyl-4H-l ,2,4-triazole-3-thiol (0.638 g, 5.54 mmol). It was sealed and purged with nitrogen. To the solids was added anhydrous DMA (5 mL). It was stirred at 100 °C until the solids completely dissolved. A solution of ieri-butyl 6-chloro-3-[(4- methoxyphenyl)sulfanyl]pyridine-2-carboxylate in hot DMA (5 mL, about 100 °C) under nitrogen was transfered to the reaction flask by a syringe and the reaction mixture was stirred in an oil bath at 140 °C for 6 h. It was cooled to rt and diluted with water (50 mL). The aqueous solution was extracted with DCM (50 mL x 4). The combined organic layers were washed with sodium carbonate twice and brine once, dried over sodium sulfate, filtrated and concentrated in vacuo. The residue was purified by Biotage (Flash 40M) gradually eluted with 0-6% MeOH in DCM to give the title compound as a yellow solid (1.36 g, 85%). *HNMR (500 MHz, CDC13) δ
(ppm) = 8.37 (s, 1H), 7.50-7.42 (m, 2H), 7.11 (d, / = 8.5 Hz, 1H), 7.06-6.95 (m, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 1.64 (s, 9H).
Step 4
Preparation of 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylic acid
The solution of ieri-butyl 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylate in wet DCM (8 mL) was added TFA (2 mL) stirring for 2 h at rt. Most solvent was removed in vacuo and the residue was purified by Biotage (Flash 25 M) gradually eluted with 100% DCM to 85:7.5:7.5 DCM:MeOH:AcOH to give the title product as an off-white solid (810 mg, 68.5%). 'HNMR (500 MHz, methanol-^) δ (ppm) = 8.72 (s, 1H), 7.47 (d, / = 8.3 Hz, 2H), 7.11 (s, 2 H), 7.05 (d, / = 8.3 Hz, 2H), 3.86 (s, 3H), 3.79 (s, 3H). Step 5
A mixture of 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylic acid (100 mg, 0.267 mmol), ethyl [(2-amino-l ,3-thiazol-5- yl)sulfanyl] acetate (70 mg, 0.32 mmol), ΗΟΒΤ (82 mg, 0.534 mmol), EDCI (102 mg, 0.534 mmol) and DIEA (0.14 mL. 0.80 mmol) in DMF (2 mL) was stirred at rt overnight. It was added 2 mL of acetonitrile, 2 mL of water, and 0.5 mL of TFA, filtrated through a 0.45 um syringe filter and purified by a Gilson HPLC system (water with 0.1 % TFA and acetonitrile with 0.1 % TFA) to afford the title compound as a yellow solid (120 mg, 78%). ESI-MS (m/e): 575.0 [M+H]+; 'HNMR (500 MHz, CDC13) δ (ppm) = 8.81 (s, 1H), 7.66 (s, 1H), 7.49 (m, 2H), 7.37 (d, J = 8.5 Hz, 1H), 7.15 (d, / = 8.5 Hz, 1H), 7.04 (m, 2H), 4.25 (q, / = 7.0 Hz, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 3.54 (s, 2H), 1.32 (t, / = 7.0 Hz, 3H).
Example 2
yl ] carbonvDaminol - 1 ,3 -thiazol-5 -yl ] sulfanyl)acetic acid
A solution of ethyl ({2-[({ 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl}carbonyl)amino]- l ,3-thiazol-5-yl} sulfanyl)acetate (120 mg, 0.209 mmol) in methanol (1 mL) and THF (1 mL) was added an aqueous solution of lithium hydroxide (2 N, 1 mL). The reaction mixture was stirred at rt for 1 h and an aqueous solution of HC1 (1 N, 2.5 mL) was added. Yellow solids were precipitated. The suspension was stirred for 30 min and the solid was filtrated, rinsed with water (5 mL), then DCM (1 mL). It was collected and dried under vacuum to afford the title compound (80 mg, 70%). ESI-MS (m/e): 547.1 [M+H]+. Example 3
3-r(4-methoxyphenyl)sulfanyll-N-(5-i r2-(methylamino)-2-oxoethyllsulfanyl]- l ,3-thiazol-2-yl)-
6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridine-2-carboxamide
A mixture of ({ 2-[({ 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4- triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]- l ,3-thiazol-5-yl}sulfanyl)acetic acid (25 mg,
0.046 mmol), methylamine (2 M in THF, 0.12 mL, 0.24 mmol), HOBT (12.36 mg, 0.091 mmol),
EDCI (17.53 mg, 0.091 mmol) in DMF (0.5 mL) was stirred at rt for three days.. Yellow precipitations were formed. The reaction mixture was diluted with ethyl acetate (2 mL ) and water (2 mL), then it was added 4 drops of 1 M HC1 by a glass pipette. The mixture was shaken for a few times and filtrated. The solid was washed in sequence with water (1 mL x 2), ethyl
acetate (1 mL x 2), methanol (0.5 mL x 2) then ether (1 mL x 2). It was collected and dried over vacuum to give 15 mg of the title compound. The filtrate was purified by HPLC to give 9 mg of the title compound. The combined yield was 24 mg (94%). ESI-MS (m/e): 560.1 [M+H]+;
'HNMR (500 MHz, DMSO-i¾ δ (ppm) = 12.0 (s, 1H), 8.83 (s, 1H), 8.02-7.92 (m, 1H), 7.61 (s, 1H), 7.48 (m, 2H), 7.07 (m, 2H), 3.80 (s, 3H), 3.62 (s, 3H), 3.44 (s, 2H), 2.59 (d, J = 4.7 Hz,
3H).
Example 4
2-(|2-r(l3-r(4-methoxyphenyl)sulfanyll-6-r(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyllpyridin-2-
Method B
Step 1
Preparation of ethyl 2-[(2-{ [(6-chloro-3-fluoropyridin-2-yl)carbonyl]amino}-l,3-thiazol-5- yl)sulfanyl] -2-methylpropanoate
A mixture of 6-chloro-3-fluoropyridine-2-carboxylic acid (314 mg, 1.786 mmol), ethyl 2-[(2- amino-l,3-thiazol-5-yl)sulfanyl]-2-methylpropanoate (400 mg, 1.624 mmol), HOBT (219 mg, 1.624 mmol), EDCI (311 mg, 1.624 mmol) in DMF (5 mL) was stirred at rt overnight. The reaction mixture was partitioned between water and diethyl ether/ethyl acetate (1/1). The aqueous layer was extracted with ether for 3 times and the combined organic layers were washed with water three times and brine once. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography eluting gradually with 10% to 40% ethyl acetate in hexane to afford the title compound as a slight yellow solid (310 mg, 54%).
Step 2
Preparation of ethyl 2-({2-[({ 6-chloro-3-[(4-methoxyphenyl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l ,3-thiazol-5-yl} sulfanyl)-2-methylpropanoate
A mixture of ethyl 2-[(2- { [(6-chloro-3-fluoropyridin-2-yl)carbonyl]amino }- l ,3-thiazol-5- yl)sulfanyl]-2-methylpropanoate (150 mg, 0.371 mmol), potassium carbonate (61.6 mg, 0.446 mmol), and 4-methoxythiophenol (62.5 mg, 0.446 mmol) were stirred in anhydrous DMF (2 mL) under nitrogen for 1.5 h at 50 °C . It was cooled to rt and left for 12 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate three times (20 mL x 3). The combined organic layers were washed with water three times (20 mL x 3), then with brine once. The organic layer was separated and dried over sodium sulfate. After concentration the residue was purifed by flash column chromatography gradually eluting with 10-40% EtOAc/Hexane to afford the title compound as a yellow glass (195 mg, 100%).
Step 3
To a flask containing ethyl 2-({2-[({ 6-chloro-3-[(4-methoxyphenyl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l ,3-thiazol-5-yl} sulfanyl)-2-methylpropanoate (195 mg, 0.372 mmol) was added 4-methyl-4H- l ,2,4-triazole-3-thiol214 mg, 1.86 mmol), potassium carbonate (209 mg, 1.86 mmol), and anhydrous DMA (2 mL). It was sealed and purged with nitrogen. The suspension was heated to 160 °C with stirring to give a clear yellow solution. After 5 h, the flask was removed from the oil bath to allow it cooled to rt. The reaction mixture was added saturated aqueous ammonium chloride (2 mL) and 20 mL of water. The mixture was extracted with ethyl acetate (20 mL x 2). The aqueous layer was acidified by 1 mL of 1 M HQ to pH 3. Chloroform
was used (20 mL x 3) to extract the product. The organic layers were combined and washed with brine, dried over sodium sulfate and concentrated in vacuo. LC-MS suggested a roughly equal amount of both ester and free acid were formed. The crude product was purified by Prep-TLC (1000 urn) developed with 5% MeOH in DCM to give the title compound (10 mg, 4.7%). ESI- MS (m/e): 575.1 [M+H]+.
Example 5
Ethyl 3-(|2-r(l 3-r(4-methoxyphenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbon yl) amino!- 1 ,3-thiazol-5-yl ] sulfanyl)-2,2-dimethylpropanoate
In the same manner as in Example 1, the title compound (44 mg, 53%) was obtained as yellow solid from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol- 3-yl)sulfanyl]pyridine-2-carboxylic acid (50 mg, 0.134 mmol) and ethyl 3-[(2-amino-l ,3-thiazol- 5-yl)sulfanyl]-2,2-dimethylpropanoate (50 mg, 0.192 mmol) and purified by HPLC. ESI-MS (m/e): 617.2 [M+H]+; 'HNMR (500 MHz, CDC13) δ (ppm) = 8.84 (s, 1H), 7.55 (s, 1H), 7.51 (m, 2H), 7.39 (d, 7 = 8.7 Hz, 1H), 7.16 (d, / = 8.7 Hz, 1H), 7.05 (m, 2H), 4.19 (q, 7 = 7.1 Hz, 2H), 3.91 (s, 3H), 3.88 (s, 3H), 3.17 (s, 2H), 1.36 (s, 6H), 1.32 (t, / = 7.1 Hz, 3H).
Example 6
3-({2 ({3 (4-methoxyphenyl)sulfanyll-6 (4-methyl-4H-1.2.4-triazol-3-yl)sulfanyllpyridin-2- yl]carbonyl)aminol-l ,3-thiazol-5-yl]sulfanyl)-2,2-dimethylpropanoic acid
In the same manner as in Example 2, the title compound (6.7 mg, 19%) was obtained as a white solid from the saponification of ethyl 3-({2-[({ 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H- l,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l ,3-thiazol-5-yl}sulfanyl)-2,2- dimethylpropanoate (37 mg, 0.060 mmol) by 1 M lithium hydroxide in methanol/water (1 : 1) at
80 °C overnight and purified by HPLC. ESI-MS (m/e): 589.0 [M+H]+; 'HNMR (500 MHz, CDC13) δ (ppm) = 8.56 (s, 1H), 7.51 (s, 1H), 7.33 (m, 2H), 7.06 (d, / = 8.7 Hz, 1H), 7.00 (m, 2H), 6.88 (d, / = 8.7 Hz, 1H), 4.01 (s, 3H), 3.91 (s, 3H), 3.21 (s, 2H), 1.46 (s, 6H). Example 7
Methyl 3-| 2-r(l 3-r(4-methoxyphenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyllpyridin-2-yl]carbonyl)aminol- l ,3-thiazol-5-yl]propanoate
In the same manner as in Example 1 , the title compound (33 mg, 76%) was obtained as yellow solid from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol- 3-yl)sulfanyl]pyridine-2-carboxylic acid (30.0 mg, 0.080 mmol) and 5-(3-methoxy-3-oxopropyl)- l ,3-thiazol-2-aminium bromide (32.2 mg, 0.120 mmol) and purified by HPLC. ESI-MS (m/e): 543.1 [M+H]+. Example 8
3-| 2-r(l 3-r(4-Methoxyphenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridin-2-
In the same manner as in Example 2, the title compound (20 mg, 79%) was obtained as a yellow solid from the saponification of methyl 3-{ 2-[({ 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l ,3-thiazol-5-yl}propanoate (37 mg, 0.060 mmol), acidification and filtration. ESI-MS (m/e): 529.1 [M+H]+.
Example 9
N-r4-(2-Amino-2-oxoethyl)phenyll-3-r(4-methoxyphenyl)sulfanyll-6-r(4-methyl-4H- l ,2,4- triazol-3-yl)sulfanyllpyridine-2-carboxamide
In the same manner as in Example 1 , the title compound was obtained from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridine-2- carboxylic acid and 2-(4-aminophenyl)acetamide and purified by HPLC. ESI-MS (m/e): 507.1 [M+H]+;
Example 10
Ethyl (| 2-r(| 3-r(4-methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonyDaminol - 1 ,3 -thiazol-5 -yl ] sulfanyDacetate
Method A
Step 1
Preparation of ieri-butyl 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridine-2- carboxylate
A solution of 2-mercaptopyridine (227 mg, 2.046 mmol) in 2 mL of DMI (dimethyl imidazolidilone) was added potassium ieri-butoxide (214 mg, 1.910 mmol) and stirred for 10 min. The solution was slowly added to ieri-butyl 6-chloro-3-[(4- methoxyphenyl)sulfanyl]pyridine-2-carboxylate (480 mg, 1.364 mmol) in 2 mL of DMI at 100 °C over 6 h and the mixture was heated for another 6 h. It was diluted with ethyl acetate (30 mL) and washed with water (30 mL x3) then brine, dried over sodium sulftate and concentrated. The
residue was purified by Biotage (Flash 25M, 0-60% ethyl acetate in hexane) to give the title compound (580 mg, 1.360 mmol, 100 % yield) as a colorless oil.
Step 2
Preparation of 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridine-2-carboxylic acid
ieri-Butyl 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridine-2-carboxylate (580 mg, 1.360 mmol) in DCM (5 ml) was added TFA (5.00 ml) and stirred for 2 h at rt. It was concentrated and diluted with DCM, washed with brine three times. Dried over sodium sulfate and concentrated to give the title compound (462 mg, 1.247 mmol, 92 % yield) as a yellow foam.
Step 3
In the same manner as Example 1 Step 5, the title compound (85 mg, 0.149 mmol, 94%) as a pale white solid was obtained from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6- (pyridin-2-ylsulfanyl)pyridine-2-carboxylic acid (59.0 mg, 0.159 mmol) and ethyl [(2-amino-l,3- thiazol-5-yl)sulfanyl]acetate (45.2 mg, 0.207 mmol) and purified by filtration. ESI-MS (m/e): 570.8 [M+H]+.
Example 11
( { 2- Γ( 13 - r(4-Methoxyphenyl)sulf anyll -6-(pyridin-2-ylsulfanyl)pyridin-2-yl ] carbonyl) amino! - 1 ,3 - thiazol-5-yl ] sulfanyDacetic acid
A solution of ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetate (80 mg, 0.140 mmol) in methanol (1 mL) and THF (1 mL) was added an aqueous solution of lithium hydroxide (2 N, 1 mL). The reaction mixture was stirred at rt for 1 h and an aqueous solution of HC1 (1 N, 3 mL) was added. Off- white solids were precipitated. The suspension was stirred for 30 min and the solid was filtrated, rinsed with water (5 mL). It was collected and dried under vacuum to afford the title compound (61 mg, 80%) as a yellow solid. ESI-MS (m/e): 542.8 [M+H]+. Example 12
Ethyl |5-chloro-2-r(|3-r(4-methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonyDaminol - 1 ,3 -thiazol-4-yl ] acetate
In the same manner as in Example 10, the title compound (47.5 mg, 0.083 mmol, 61%) was obtained as yellow solid from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (50 mg, 0.135 mmol) and ethyl (2-amino-5-chloro-l,3- thiazol-4-yl)acetate (38.7 mg, 0.175 mmol) and purified by HPLC. ESI-MS (m/e): 572.9
[M+H]+. Example 13
|5-Chloro-2-r(|3-r(4-methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonyDaminol - 1 ,3 -thiazol-4-yl ] acetic acid
In the same manner as in Example 11, the title compound (28 mg, 74%) was obtained as an yellow solid from the saponification of ethyl ethyl {5-chloro-2-[({3-[(4- methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3-thiazol-4- yl}acetate (40 mg, 0.070 mmol) by 0.5 M lithium hydroxide in methanol/water/THF (2:1: 1, 2 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 544.8
[M+H]+. Example 14
Methyl 3-{2-r(l3-r(4-methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-
In the same manner as in Example 10, the title compound (65 mg, 0.121 mmol, 89%) was obtained as yellow solid from the amide coupling of 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (50 mg, 0.135 mmol) and 5-(3-methoxy-3-oxopropyl)-l,3- thiazol-2-aminium bromide (50.5 mg, 0.189 mmol) and purified by HPLC. ESI-MS (m/e): 538.9 [M+H]+. Example 15
3-{2-r(l3-r(4-Methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-yl]carbonyl)amm^ 1, 3 -thiazol-5-yl] propanoic acid
In the same manner as in Example 11, the title compound (50 mg, 86%) was obtained as an yellow solid from the saponification of methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6- (pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5-yl}propanoate (60 mg, 0.111 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1:1 :1, 1.5 rriL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 524.9 [M+H]+. 'HNMR (500 MHz, DMSO-i¾) δ (ppm) = 12.2 (bs, 1H), 11.8 (s, 1H), 8.53 (m, 1H), 7.81 (td, / = 7.9, 1.9 Hz, 1H), 7.58-7.48 (m, 4H), 7.34 (dd, / = 7.5, 4.8 Hz, 1H), 7.12 (m, 3H), 6.95 (s, 1H), 3.83 (s, 3H), 2.89 (t, J = 7.4 Hz, 2H), 2.64 (t, J = 7.6 Hz, 2H). Example 16
Ethyl |2-r(|3-r(4-methoxyphenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonvDaminol - 1 ,3 -thiazol-4-yl ] acetate
In the same manner as in Example 10, 3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (50 mg, 0.135 mmol) and ethyl (2-amino-l,3-thiazol-4- yl)acetate (35.2 mg, 0.189 mmol) was coupled. The product was precipitated by the addition of 2 mL of water and 0.3 mL of TFA. The solid filtrated and washed with water/acetonitrile (10/1), then diethyl ether in sequence. It was dried under high vacuum to give the title compound (68 mg, 94%) as yellow solid. ESI-MS (m/e): 538.8 [M+H]+.
Example 17
|2-r(|3-r(4-Methoxyphenyl)sulfanyll-6-(p idin-2-ylsulfanyl)pyridin-2-yl]carbonyl)aminol-l,3- thiazol-4-yl] acetic acid
In the same manner as in Example 11, the title compound (48 mg, 84%) was obtained as an yellow solid from the saponification of ethyl {2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-
ylsulfanyl)pyridin-2-yl}carbonyl)amino]- l ,3-thiazol-4-yl} acetate (60 mg, 0.11 1 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1 : 1 : 1 , 1.5 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 510.8 [M+H]+. Example 18
Ethyl ({ 5-\(\ 3-r(4-fluorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridin-2- yl ] carbonyl)aminolthiophen-2-yl ] sulfanyDacetate
Step 1
A solution of 3,6-dichloropyridine-2-carboxylic acid (25 g, 130 mmol) and ieri-butyl 2,2,2- trichloroacetimidate (25 ml, 140 mmol) in DCM (200 ml) was added BF3.OEt2 (lmL, 7.89 mmol) and the mixture was stirred for 2 d. TLC showed that starting material ("SM") remained. One more equiv of -butyl 2,2,2-trichloroacetimidate (25 ml, 140 mmol) was added stirring for 2 d. TLC showed the completion of the reaction. To the mixture was added 2 mL of TEA. The mixture was filtrated through Celite and the filtrate was washed with sodium bicarbonate, then brine. Dried over sodium sulfate and concentrated. The residue was purified by Biotage (Flash 65M, 0-30% ethyl acetate in hexane with 2% TEA) to give the title compound (31.0 g, 125 mmol, 96 % yield) as white crystals.
Step 2
Prep
The suspension of potassium carbonate (4.27 g, 30.9 mmol), 4-fluorothiophenol (3.29 ml, 30.9 mmol) and ieri-butyl 3,6-dichloropyridine-2-carboxylate (5.11 g, 20.60 mmol) in DMF (20 ml) was stirred overnight at rt. TLC showed significant amount of starting material left. The reaction mixture was heated at 50 °C for 1 h. It was diluted with 200 mL of water and extracted with diethyl ether twice. The combined organic layers were washed with water five times (100 mL) and brine once. It was dried over sodium sulfate and concentrated. The residue was purified by Biotage (Flash 65M, 0-30% ethyl acetate in hexane) to afford ieri-butyl 6-chloro-3-[(4- fluorophenyl)sulfanyl]pyridine-2-carboxylate (2.53 g, 7.45 mmol, 36.1 % yield) as white crystals and ieri-butyl 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylate (4.30 g, 9.96 mmol, 48.4 % yield) as white crystals.
Step 3
Preparation of ieri-butyl 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridine- -carboxylate
A solution of 3-mercapto-4-methyl-4H-l,2,4-triazole (136 mg, 1.177 mmol) in 2.5 mL of DMI was added potassium ieri-Butoxide (132 mg, 1.177 mmol) stirring for 20 min. The solution was slowly added to a solution of ieri-butyl 6-chloro-3-[(4-fluorophenyl)sulfanyl]pyridine-2- carboxylate (200 mg, 0.589 mmol) in 2.5 mL of DMI at 100 °C by a syringe pump over 6 h. It was heated for another 6 h after the addition. The reaction mixture was cooled to rt, diluted with 50 mL of water, extracted with ethyl acetate twice. The organic layers were washed with water three times and brine once, dried over sodium sulfate, filtrated and concentrated in vacuo. The residue was purified by Biotage (ethyl acetate) to give the title compound (224 mg, 0.535 mmol, 91 % yield) as a pale white solid.
Step 4
Preparation of 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridine- 2-carboxylic acid
A solution of ieri-butyl 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylate (210 mg, 0.502 mmol) in DCM (4 ml) was added TFA (2 mL) at 0 °C. The reaction was warmed to rt and stirred for 1 h. It was concentrated in vacuo and diluted with 20 mL DCM. It was washed with brine once. The organic layer was dried over sodium sulfate, filtrated and concentrated in vacuo. The solid was triturated in diethyl ether and filtrated to give the title compound (168 mg, 0.464 mmol, 92 % yield) as a white solid.
In the same manner as Example 1 Step 5, the title compound (63 mg, 0.112 mmol, 68%) as a yellow solid was obtained from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6- [(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxylic acid (60.0 mg, 0.166 mmol) and ethyl [(2-amino-l,3-thiazol-5-yl)sulfanyl]acetate (47.0 mg, 0.215 mmol) and purified by HPLC. ESI-MS (m/e): 562.9 [M+H]+.
Example 19
(|2-r(l3-r(4-Fluorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridin-2- yl ] carbonyDaminol - 1 ,3 -thiazol-5 -yl ] sulfanyDacetic acid
A solution of ethyl ({5-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2-yl}sulfanyl)acetate (58 mg, 0.103 mmol) in
methanol (1 mL) and THF (1 mL) was added an aqueous solution of lithium hydroxide (2 N, 1 mL). The reaction mixture was stirred at rt for 1 h and an aqueous solution of HC1 (1 N, 3 mL) was added. Yellow solids were precipitated. The suspension was stirred for 30 min and the solid was filtrated, rinsed with water (5 mL). It was collected and dried under vacuum to afford the title compound (47.6 mg, 86%) as a yellow solid. ESI-MS (m/e): 535.1 [M+H]+.
Example 20
Ethyl 3-( { 5-Γ(13-r(4-fluorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanvHpyridin- 2-yl ] carbonyl)aminolthiophen-2-yl ] sulfanyl)-2,2-dimethylpropanoate
In the same manner as in Example 1, the title compound (62 mg, 0.103 mmol, 62%) was obtained as yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl- 4H-l,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxylic acid (60.0 mg, 0.166 mmol) and ethyl 3-[(2- amino-l,3-thiazol-5-yl)sulfanyl]-2,2-dimethylpropanoate (56 mg, 0.215 mmol) and purified by HPLC. ESI-MS (m/e): 605.0 [M+H]+.
Example 21
3-(|2-r(l3-r(4-Fluorophenyl)sulfanyll-6-r(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyllpyridin-2- yl]carbonyl)aminol-l,3-thiazol-5-yl]sulfanyl)-2,2-dimethylpropanoic acid
In the same manner as in Example 2, the title compound (37 mg, 72%) was obtained as a white solid from the saponification of ethyl ethyl 3-({5-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl- 4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2-yl}sulfanyl)-2,2- dimethylpropanoate (54 mg, 0.089 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1:1 :1) at 70 °C for 1 h and purified by HPLC. ESI-MS (m/e): 576.8 [M+H]+.
Example 22
Ethyl ( 2-IY ( 3-r(4-fluorophenvDsulfanyll-6-r(4-methyl-4H- 1.2.4-triazol-3-vDsulfanyllpyridin-2- yl ] carbonvDaminol - 1 ,3 -thiazol-5 -yl ] acetate
In the same manner as in Example 1 , the title compound (31 mg, 0.058 mmol, 76%) was obtained as a yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl- 4H- l ,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxylic acid (28.0 mg, 0.077 mmol) and ethyl (2- amino-l ,3-thiazol-4-yl)acetate (18.7 mg, 0.100 mmol) and purified by HPLC. ESI-MS (m/e): 531.0 [M+H]+.
Example 23
|2-r(l 3-r(4-Fluorophenyl)sulfanyll-6-r(4-methyl-4H- l ,2,4-triazol-3-yl)sulfanyllpyridin-2- yl ] carbonvDaminol - 1 ,3 -thiazol-5 -yl ] acetic acid
In the same manner as in Example 11 , the title compound (23 mg, 93%) was obtained as an off- white solid from the saponification of ethyl {2-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H- l ,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino] -1 ,3 -thiazol-5 -yl} acetate (26 mg, 0.049 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1 : 1 : 1 , 1.5 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 502.8 [M+H]+.
Example 24
Ethyl { 5-chloro-2-r(l 3-r(4-fluorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbonvDaminol- 1 ,3-thiazol-4-yl ] acetate
In the same manner as in Example 1 , the title compound (27.6 mg, 30%) was obtained as a yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4- triazol-3-yl)sulfanyl]pyridine-2-carboxylic acid (60.0 mg, 0.166 mmol) and ethyl (2-amino-5- chloro-l ,3-thiazol-4-yl)acetate (47.5 mg, 0.215 mmol) and purified by HPLC. ESI-MS (m/e): 564.8 [M+H]+.
Example 25
{ 5-Chloro-2 ({ 3-i(4-fluorophenyl)sulfany
2-yl ] carbonvDaminol - 1 ,3 -thiazol-4-yl ] acetic acid
In the same manner as in Example 11 , the title compound (19.3 mg, 81 ) was obtained as a slight yellow solid from the saponification of ethyl { 5-chloro-2-[({ 3-[(4-fluorophenyl)sulfanyl]- 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l ,3-thiazol-4- yl} acetate (25 mg, 0.044 mmol) by 0.1 M lithium hydroxide in methanol/water/THF (1 : 1 : 1 , 2 mL) at rt for 1 h, acidification by 3 mL of 1 N HCl and filtration. ESI-MS (m/e): 536.7 [M+H]+.
Example 26
Diethyl ({ 2-r(l 3-r(4-fluorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyllpyridin- 2-yl ] carbonvDaminol - 1 ,3 -thiazol-5 -yl ] methyDphosphonate
In the same manner as in Example 1, the title compound (57.4 mg, 87%) was obtained as a white solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyl]pyridine-2-carboxylic acid (40.0 mg, 0.110 mmol) and ethyl (2-amino-5-chloro-l,3- thiazol-4-yl)acetate (30.4 mg, 0.121 mmol) and purified by filtration. ESI-MS (m/e): 594.8
[M+H]+.
Example 27
Ethyl (15-Γ(13,6-bisr(4-fluorophenyl)sulfanyllpyridin-2-yl]carbonyl)aminolthiophen-2- yl ] sulfanyDacetate
Step 1
A solution of ieri-butyl 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylate (4.38 g, 10.15 mmol) in DCM (40 ml) and TFA (20 ml) was stirred for 6 h at rt. TLC showed the completion of the reaction. Solvents were removed in vacuo. The yellow residue was purified by Biotage (Flash 65M, 0-10% DCM:methanol/acetic acid (1/1)). The fractions were concentrated to give a white solid, which was triturated in 30 mL of diethyl ether and filtrated, rinsed with diethyl ether to give 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylic acid (2.4 g, 6.39 mmol, 63.0 % yield) as a yellow solid. Step 2
In the same manner as in Example 1, the title compound (56 mg, 64%) was obtained as a pale yellow solid from the amide coupling of 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylic acid (57.0 mg, 0.152 mmol) and ethyl [(2-amino-l,3-thiazol-5-yl)sulfanyl]acetate (33.1 mg, 0.152 mmol) and purified by filtration. ESI-MS (m/e): 576.0 [M+H]+.
Example 28
(|2-r(|3,6-Bisr(4-fluorophenyl)sulfanyllpyridin-2-yl]carbonyl)aminol-l,3-thiazol-5- yl]sulfanyl)acetic acid
In the same manner as in Example 11, the title compound (49 mg, 99%) was obtained as a slight yellow solid from the saponification of ethyl ({5-[({3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2- yl}carbonyl)amino]thiophen-2-yl}sulfanyl)acetate (52 mg, 0.090 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1 :1 :1, 3 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HCl and filtration. ESI-MS (m/e): 548.0 [M+H]+.
Example 29
Ethyl { 2-Γ( 13,6-bisr(4-fluorophenyl)sulfanyHpyridin-2-yl ]carbonyl)aminol-5-chloro- 1 ,3-thiazol- 4-yll acetate
In the same manner as in Example 1 , the title compound (74 mg, 80%) was obtained as a pale yellow solid from the amide coupling of 3,6-bis[(4-fluorophenyl)sulfanyl]pyridine-2-carboxylic acid (60.0 mg, 0.160 mmol) and ethyl (2-amino-5-chloro-l,3-thiazol-4-yl)acetate (49.4 mg, 0.224 mmol) and purified by HLPC. ESI-MS (m/e): 577. [M+H]+.
Example 30
{ 2- Γ( 13 ,6-Bis r(4-fluorophenyl)sulfanyHpyridin-2-yl ] carbonyDaminol -5 -chloro- 1 ,3 -thiazol-4- yl] acetic acid
In the same manner as in Example 11, the title compound (60 mg, 94%) was obtained as a slight yellow solid from the saponification of ethyl {2-[({3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2- yl}carbonyl)amino]-5-chloro-l,3-thiazol-4-yl}acetate (67 mg, 0.116 mmol) by 0.67 M lithium
hydroxide in methanol/water/THF (1 :1 :1, 3 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HCl and filtration. ESI-MS (m/e): 549.8 [M+H]+.
Example 31
Ethyl {5-chloro-2-r(l3-r(4-fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonvDaminol - 1 ,3 -thiazol-4-yl ] acetate
In the same manner as in Example 10, the title compound (56.5 mg, 72%) was obtained as a pale yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (50.0 mg, 0.140 mmol) and ethyl (2-amino-5-chloro-l,3- thiazol-4-yl)acetate (43.1 mg, 0.195 mmol) and purified by HLPC. ESI-MS (m/e): 560.8
[M+H]+.
Example 32
|5-Chloro-2-r(|3-r(4-fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2- yl ] carbonvDaminol - 1 ,3 -thiazol-4-yl ] acetic acid
In the same manner as in Example 11, the title compound (60 mg, 94%) was obtained as a yellow solid from the saponification of ethyl {2-[({3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2- yl}carbonyl)amino]-5-chloro-l,3-thiazol-4-yl}acetate (67 mg, 0.116 mmol) by 0.67 M lithium hydroxide in methanol/water/THF (1 :1 :1, 3 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HCl and filtration. ESI-MS (m/e): 532.7 [M+H]+.
Example 33
Ethyl |2-r(|3-r(4-fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-yl]carbonyl)aminol-
In the same manner as in Example 10, the title compound (40 mg, 68%) was obtained as a pale yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (40.0 mg, 0.112 mmol) and ethyl (2-amino-l,3-thiazol-4- yl)acetate (29.1 mg, 0.156 mmol) and purified by HLPC. ESI-MS (m/e): 526.9 [M+H]+.
Example 34
|2-r(|3-r(4-Fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-yl]carbonyl)aminol-l,3- thiazol-4-yl] acetic acid
In the same manner as in Example 11, the title compound (21 mg, 65%) was obtained as a yellow solid from the saponification of ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3-thiazol-4-yl}acetate (34 mg, 0.065 mmol) by 1 M lithium hydroxide in water/THF (1 :1, 2 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HCl and filtration. ESI-MS (m/e): 498.8 [M+H]+.
Example 35
Ethyl ({2-r(j3-r(4-fluorophenyl)sulfanyll-6-(pyridin^
l,3-thiazol-5-yl]sulfanyl)acetate
In the same manner as in Example 10, the title compound (45 mg, 72%) was obtained as a pale yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-
ylsulfanyl)pyridine-2-carboxylic acid (40.0 mg, 0.112 mmol) and ethyl [(2-amino-l,3-thiazol-5- yl)sulfanyl]acetate (34.1 mg, 0.156 mmol) and purified by HLPC. ESI-MS (m/e): 558.8 [M+H]+.
Example 36
({2-r(l3-r(4-Fluorophenyl)sulfanyll-6-(pyr ^
thiazol-5-yl ] sulfanyl)acetic acid
In the same manner as in Example 11, the title compound (38 mg, 100%) was obtained as a yellow solid from the saponification of ethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetate (40 mg, 0.072 mmol) by 0.67 M lithium hydroxide in MeOH/water/THF (1:1 : 1, 1.5 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 530.8 [M+H]+.
Example 37
Ethyl 3-(|2-r(|3-r(4-fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-
In the same manner as in Example 10, the title compound (45 mg, 67%) was obtained as a pale yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (40.0 mg, 0.112 mmol) and ethyl 3-[(2-amino-l,3-thiazol- 5-yl)sulfanyl]-2,2-dimethylpropanoate (40.7 mg, 0.156 mmol) and purified by HLPC. ESI-MS (m/e): 600.9 [M+H]+.
Example 38
3-({2-r(l3-r(4-Fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-yl]carbonyl)aminol-l,3 thiazol-5-yl ] sulfanyl)-2,2-dimethylpropanoic acid
In the same manner as in Example 2, the title compound (26 mg, 72%) was obtained as a yellow solid from the saponification of ethyl 3-({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoate (38 mg, 0.063 mmol) by 0.67 M lithium hydroxide in MeOH/water/THF (1:1 :1, 1.5 mL) at 50 °C for 2 h, acidification by 2.5 mL of 1 N HC1 and purification by HPLC. ESI-MS (m/e): 572.9
[M+H]+.
Example 39
Methyl 3 - 12- Γ( 13- Γ( 4-fluorophenyl)sulf anyll -6-( pyridin-2- ylsulf anyl)pyridin-2-
In the same manner as in Example 10, the title compound (54 mg, 92%) was obtained as a pale yellow solid from the amide coupling of 3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2- ylsulfanyl)pyridine-2-carboxylic acid (40.0 mg, 0.112 mmol) and 5-(3-methoxy-3-oxopropyl)- l,3-thiazol-2-aminium bromide (29.8 mg, 0.112 mmol) and purified by HLPC. ESI-MS (m/e): 526.9 [M+H]+.
Example 40
3-|2-r(|3-r(4-Fluorophenyl)sulfanyll-6-(pyridin-2-ylsulfanyl)pyridin-2-yl]carbonyl)aminol- thiazol-5-yl]propanoic acid
In the same manner as in Example 2, the title compound (31 mg, 66%) was obtained as a yellow solid from the saponification of methyl 3-{2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-
ylsulfanyl)pyridin-2-yl}carbonyl)amino]- l ,3-thiazol-5-yl}propanoate (48 mg, 0.091 mmol) by 0.67 M lithium hydroxide in MeOH/water/THF (1 : 1 : 1 , 1.5 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HC1 and purification by HPLC. ESI-MS (m/e): 512.8 [M+H]+. Example 41
Ethyl (5-chloro-2-{ r(6-r(4-methyl-4H- l ,2,4-triazol-3-yl)sulfanyll-3-{ Γ4-
(trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino ]- l ,3-thiazol-4-yl)acetate
In the same manner as in Example 1 , the title compound (31 mg, 52%) was obtained as a yellow solid from the amide coupling of 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl (2- amino-5-chloro- l ,3-thiazol-4-yl)acetate (32 mg, 0.145 mmol) and purified by HLPC. ESI-MS (m/e): 614.8 [M+H]+. Example 42
(5-Chloro-2- { Γ(6- r(4-methyl-4H- 1.2.4-triazol-3-yl)sulfanyll-3- f Γ4-
(trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino ]- l ,3-thiazol-4-yl)acetic acid
In the same manner as in Example 11 , the title compound (22.6 mg, 62%) was obtained as a yellow solid from the saponification of ethyl (5-chloro-2-{ [(6-[(4-methyl-4H- l ,2,4-triazol-3- yl)sulfanyl]-3-{ [4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino} -l ,3-thiazol-4- yl)acetate (29 mg, 0.047 mmol) by 1 M lithium hydroxide in MeOH/water (1 : 1 , 1 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 587.1 [M+H]+. Example 43
Ethyl r(2-{r(6-r(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyll-3- { r4-
In the same manner as in Example 1 , the title compound (41.8 mg, 70.3%) was obtained as a yellow solid from the amide coupling of 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl] sulf anyl }pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl [(2-amino- l ,3-thiazol-5-yl)sulfanyl]acetate (27.5 mg, 0.126 mmol) and purified by HLPC. ESI- MS (m/e): 612.8 [M+H]+. Example 44
r(2-{r(6-r(4-Methyl-4H- 1.2.4-triazol-3-yl)sulfanyll-3- { r4-
(trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino ]- l ,3-thiazol-5-yl)sulfanyllacetic acid
In the same manner as in Example 11 , the title compound (32 mg, 88%) was obtained as a yellow solid from the saponification of ethyl [(2- { [(6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3- { [4- (trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino }- l ,3-thiazol-5-yl)sulfanyl]acetate (38 mg, 0.062 mmol) by 1 M lithium hydroxide in MeOH/water (1 : 1 , 1 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 585.1 [M+H]+.
Example 45
Diethyl r(2-{r(6-r(4-methyl-4H-1.2.4-triazol-3-yl)sulfanyll-3-{r4-
(trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino ]- l ,3-thiazol-5- vDmethyllphosphonate
In the same manner as in Example 1, the title compound (53 mg, 85%) was obtained as a yellow solid from the amide coupling of 6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl]sulfanyl}pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and diethyl [(2-amino-l,3-thiazol-5-yl)methyl]phosphonate (26.7 mg, 0.107 mmol) and purified by HLPC. ESI-MS (m/e): 644.8 [M+H]+.
Example 46
Ethyl (2-{r(6-r(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyll-3-{r4- (trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino]-l,3-thiazol-4-yl)acetate
In the same manner as in Example 1, the title compound (56 mg, 99%) was obtained as a pale white solid from the amide coupling of 6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl]sulfanyl}pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl (2- amino-l,3-thiazol-4-yl)acetate (25.3 mg, 0.136 mmol) and purified by filtration. ESI-MS (m/e): 580.9 [M+H]+.
Example 47
(2- { Γ(6- r(4-Methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyll-3- { Γ4- (trifluoromethyl)phenyllsulfanyl]pyridin-2-yl)carbonyllamino]-l,3-thiazol-4-yl)acetic acid
In the same manner as in Example 11 , the title compound (36.5 mg, 77%) was obtained as a yellow solid from the saponification of ethyl (2-{ [(6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]- 3 - { [4-(trifluoromethyl)phenyl] sulfanyl }pyridin-2-yl)carbonyl] amino } - 1 ,3 -thiazol-4-yl)acetate (50 mg, 0.086 mmol) by 0.67 M lithium hydroxide in MeOH/water (1 : 1 : 1 , 1.5 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and purification by HPLC. ESI-MS (m/e): 552.8 [M+H]+.
Example 48
Methyl 3-(2- { r(6-r(4-methyl-4H- l ,2,4-triazol-3-yl)sulfanyll-3- { Γ4-
In the same manner as in Example 1 , the title compound (39.4 mg, 70%) was obtained as a pale yellow solid from the amide coupling of 6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl] sulfanyl }pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and 5-(3- methoxy-3-oxopropyl)-l ,3-thiazol-2-aminium bromide (36.3 mg, 0.136 mmol) and purified by HPLC. ESI-MS (m/e): 580.9 [M+H]+.
Example 49
3-(2- 1 Γ(6- r(4-Methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyll-3- { Γ4-
In the same manner as in Example 11 , the title compound (22.5 mg, 70%) was obtained as a yellow solid from the saponification of methyl 3-(2-{ [(6-[(4-methyl-4H- l ,2,4-triazol-3- yl)sulfanyl] -3 - { [4-(trifluoromethyl)phenyl] sulfanyl } pyridin-2-yl)carbonyl] amino } - 1 ,3-thiazol-5 - yl)propanoate (33 mg, 0.057 mmol) by 0.67 M lithium hydroxide in MeOH/water (1 : 1 : 1 , 1.5 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and purification by HPLC. ESI-MS (m/e): 566.8 [M+H]+.
Example 50
Diethvi 2-r 3-r .4-dichlorophenyl)sulfanyll-6-r(4-methyl-4H-1.2.4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbonyl) amino!- 1 ,3-thiazol-5-yl ] methvDphosphonate
In the same manner as in Example 1 , the title compound (59 mg, 94%) was obtained as a yellow solid from the amide coupling of 3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol- 3-yl)sulfanyl]pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and diethyl [(2-amino-l ,3- thiazol-5-yl)methyl]phosphonate (26.6 mg, 0.106 mmol) and purified by HPLC. ESI-MS (m/e): 644.9 [M+H]+.
Example 51
Ethyl ({ 2-r({ 3-r(3.4-dichlorophenyl)sulfanyll-6-r(4-methyl-4H-1.2.4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbonyDaminol- 1 ,3-thiazol-5-yl ] sulfanvDacetate
In the same manner as in Example 1 , 3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4- triazol-3-yl)sulfanyl]pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl [(2-amino-l ,3- thiazol-5-yl)sulfanyl]acetate (27.5 mg, 0.126 mmol) was coupled in 1 mL of DMF. The reaction mixture was diluted with 2 mL of water and 0.3 mL of TFA to precipitate the desired product. It was filtrated and rinsed with 5 mL of water and 3 mL of acetonitrile. The pale white solid was collected and dried under high vacuum to give the title compound (50.3 mg, 85%). ESI-MS (m/e): 612.9 [M+H]+.
Example 52
({2-r({ 3-r(3.4-Dichlorophenyl)sulfanyll-6-r(4-methyl-4H-1.2.4-triazol-3-yl)sulfanyllpyridin-2- yl ] carbonyDaminol - 1 ,3 -thiazol-5 -yl ] sulfanyDacetic acid
In the same manner as in Example 11 , the title compound (22.5 mg, 70%) was obtained as a yellow solid from the saponification of ethyl ({ 2-[({ 3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4- methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl } carbonyl)amino]- 1 ,3-thiazol-5- yl} sulfanyl)acetate (35 mg, 0.057 mmol) by 0.67 M lithium hydroxide in MeOH/water (1 : 1 : 1 , 3 mL) at rt for 1 h, acidification by 2.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 584.7
[M+H]+.
Example 53
Ethyl { 5-chloro-2-r(l 3-r(3,4-dichlorophenyl)sulfanyll-6-r(4-methyl-4H-l ,2,4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbonyl) amino!- 1 ,3-thiazol-4-yl ] acetate
In the same manner as in Example 1 , the title compound (45 mg, 75%) was obtained as a yellow solid from the amide coupling of 3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol- 3-yl)sulfanyl]pyridine-2-carboxylic acid (40.0 mg, 0.097 mmol) and ethyl (2-amino-5-chloro- l ,3- thiazol-4-yl)acetate (27.8 mg, 0.126 mmol) and purified by HPLC. ESI-MS (m/e): 614.7
[M+H]+.
Example 54
{ 5-Chloro-2-r({ 3-r(3,4-dichlorophenyl)sulfanyll-6-r(4-methyl-4H- l ,2,4-triazol-3- yl)sulfanyllpyridin-2-yl ] carbonyl) amino!- 1 ,3-thiazol-4-yl ] acetic acid
In the same manner as in Example 11, the title compound (31 mg, 79%) was obtained as a yellow solid from the saponification of ethyl {5-chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4- methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetate (41 mg, 0.067 mmol) by 0.67 M lithium hydroxide in MeOH/water (1 :1:1, 1.5 mL) at rt for 1 h, acidification by 1.5 mL of 1 N HC1 and filtration. ESI-MS (m/e): 586.7 [M+H]+.
While the invention has been described and illustrated in reference to specific embodiments thereof, various changes, modifications, and substitutions can be made therein without departing from the invention. For example, alternative effective dosages may be applicable, based upon the responsiveness of the patient being treated. Likewise, the pharmacologic response may vary depending upon the particular active compound selected, formulation and mode of administration. All such variations are included within the present invention.
Claims
1. A compound of formula I:
(I)
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 individually represent 6- to 10-membered aryl group, 5- to 10-membered heteroaryl group, a 5- to 7- membered cycloalkyl group, or a 5- to 7-membered aliphatic heterocyclic group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_6alkylC(0)i_2Ci_ 6alkyl, Ci_6alkylS(0)o-2, S(0)o-2 or arylCi_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens;
ring A represents a 5- to 7-membered monocyclic or 9- to 10-membered bicyclic heteroaryl group in which the carbon atom attached to the amide nitrogen atom contained in formula (I) forms C=N together with the nitrogen atom in the ring,
wherein ring A, in addition to the -L-T substituent, is further optionally substituted with 1 -4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_ 6alkoxy, C1_6alkylS(O)0-2, CN, NR3R4, C(0)1_2C1_6alkyl, C1_6alkylC(0)1_2C1_6alkyl or S(O)0-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, Ci_6alkyl or Ci_6alkoxy where the alkyl and alkoxy substituents are optionally substituted by 1-6 halogens,
L represents Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, NR3R4, Ci_6alkylNR3R4, S(O)0-2Ci_6alkyl or S(0)o-2, wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens,
T represents C02R, CONR3R4, or P(0)(OR5)2, and
R, R3, R4, and R5 are individually selected from hydrogen or Ci_6alkyl.
2. A compound of claim 1, wherein R1 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_6alkylC(0)i_2Ci_ 6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 or 2, wherein R1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_6alkylC(0)i_2Ci_6alkyl, Ci_ 6alkylS(0)o-2, S(0)o-2 or arylCi_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
.
4. A compound of any of claims 1-3, wherein R1 is triazolyl, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen or Ci_6alkyl, wherein the alkyl is further optionally substituted by 1-6 halogen substituents; or a
pharmaceutically acceptable salt thereof.
5. A compound of any of claims 1-4, wherein R2 is a 5-6-membered aryl or heteroaryl group, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, Ci_6alkyl, Ci_6alkylOCi_6alkyl, Ci_6alkoxy, CN, NR3R4, C(0)i_2Ci_6alkyl, Ci_ 6alkylC(0)i-2Ci_6alkyl, Ci_6alkylS(0)o-2 or S(0)o-2, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or Ci_ 6alkyl where said Ci_6alkyl is optionally substituted by 1-6 halogens; or a pharmaceutically acceptable salt thereof.
6. A compound of any of claims 1-5, wherein R2 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, Ci_6alkoxy, or Ci_6alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
7. A compound of any of claims 1-6, wherein ring A is a substituted 5-6-membered aryl or heteroaryl group; or a pharmaceutically acceptable salt thereof.
8. A compound of any of claims 1-7, wherein ring A is a substituted thiazolyl or phenyl group; or a pharmaceutically acceptable salt thereof.
9. A compound of any of claims 1-8, wherein ring A is a substituted thiazolyl group; or a pharmaceutically acceptable salt thereof.
10. A compound of any of claims 1-9, wherein L represents Ci-6alkyl or S(0)o-2Ci_ 6alkyl, further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.
11. A compound of any of claims 1-10, wherein L represents -SCH2-, SC(CH3)2-, - SCH2C(CH3)2-, -CH2CH2- or -CH2-; or a pharmaceutically acceptable salt thereof.
12. A compound which is:
Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin- 2-yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetate;
( { 2- [( { 3 - [(4-methoxyphenyl)sulf anyl] -6- [(4-methyl-4H- 1 ,2,4-triazol-3 -yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } sulfanyl)acetic acid;
3-[(4-methoxyphenyl)sulfanyl]-N-(5-{ [2-(methylamino)-2-oxoethyl]sulfanyl}-l,3-thiazol-2-yl)-
6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide;
2-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2-methylpropanoic acid;
Ethyl 3-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } sulfanyl)-2,2-dimethylpropanoate;
3-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2,2-dimethylpropanoic acid;
Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5-yl}propanoate;
3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l ,3 -thiazol-5 -yl} propanoic acid;
N-[4-(2-Amino-2-oxoethyl)phenyl]-3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4- triazol-3-yl)sulfanyl]pyridine-2-carboxamide;
Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)acetate yridine-2-carboxamide;
( { 2- [( { 3 - [(4-Methoxyphenyl)sulf anyl] -6-(pyridin-2-ylsulfanyl)pyridin-2-yl } carbonyl) amino] -1,3- thiazol-5-yl}sulfanyl)acetic acid;
Ethyl {5-chloro-2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetic acid;
Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } propanoate;
3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- 1,3 -thiazol-5 -yl} propanoic acid;
Ethyl {2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-4-yl} acetic acid;
Ethyl ({ 5-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino]thiophen-2-yl } sulfanyl)acetate;
({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)acetic acid;
Ethyl 3-({ 5-[({ 3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l ,2,4-triazol-3-yl)sulfanyl]pyridin-
2- yl } carbonyl)amino]thiophen-2-yl } sulfanyl)-2,2-dimethylpropanoate;
3- ({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino] -1,3 -thiazol-5 -yl}sulfanyl)-2,2-dimethylpropanoic acid;
Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } acetate;
{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } acetic acid;
Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin- 2-yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetic acid;
Diethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin- 2-yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } methyl)phosphonate;
Ethyl ({ 5-[({ 3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2- yl}sulfanyl)acetate;
({2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-l,3-thiazol-5- yl}sulfanyl)acetic acid;
Ethyl { 2-[({ 3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl }carbonyl)amino]-5-chloro- 1 ,3-thiazol- 4-yl} acetate;
{2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-5-chloro-l,3-thiazol-4- yl} acetic acid;
Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-4-yl } acetic acid;
Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- l,3-thiazol-4-yl}acetate;
{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-4-yl} acetic acid;
Ethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]- 1 ,3-thiazol-5-yl} sulfanyl)acetate;
({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl } sulfanyl)acetic acid;
Ethyl 3-({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoate;
3-({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoic acid;
Methyl 3-{2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2- yl } carbonyl)amino] - 1 ,3 -thiazol-5 -yl } propanoate;
3-{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-l,3- thiazol-5-yl}propanoic acid;
Ethyl (5-chloro-2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetate;
(5-Chloro-2- { [(6- [(4-methyl-4H- 1 ,2,4-triazol-3-yl)sulfanyl]-3- { [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetic acid; Ethyl [(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)sulfanyl]acetate; [(2-{ [(6-[(4-Methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)sulfanyl]acetic acid;
Diethyl [(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5- yl)methyl]phosphonate;
Ethyl (2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4- (trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetate;
(2-{ [(6-[(4-Methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-4-yl)acetic acid; Methyl 3-(2-{ [(6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)propanoate; 3-(2-{ [(6-[(4-Methyl-4H-l,2,4-triazol-3-yl)sulfanyl]-3-{ [4-
(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-l,3-thiazol-5-yl)propanoic acid;
Diethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } methyl)phosphonate;
Ethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-5-yl } sulfanyl)acetate;
({2-[({3-[(3,4-Dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3-yl)sulfanyl]pyridin-2- yl}carbonyl)amino]-l,3-thiazol-5-yl}sulfanyl)acetic acid;
Ethyl {5-chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetate;
{5-Chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-l,2,4-triazol-3- yl)sulfanyl]pyridin-2-yl } carbonyl) amino]- 1 ,3-thiazol-4-yl } acetic acid; or
a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound of any of claims 1-12, and a pharmaceutically acceptable carrier.
14. Use of a compound of any of claims 1-12 in the manufacture of a medicament for use in treating a condition selected from obesity or diabetes.
15. Use of a compound of any of claims 1-12 in the treatment of diabetes.
16. A method for the treatment of a condition selected from obesity or diabetes comprising administering to an individual a pharmaceutical composition comprising the compound of any of claims 1-12.
17. The method of claim 15 where the compound of any of claims 1-12 is used in combination with one or more other active ingredients.
18. Use of a compound of any of claims 1-12 in therapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13865833.1A EP2931718B1 (en) | 2012-12-17 | 2013-12-12 | Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment |
US14/652,944 US9527838B2 (en) | 2012-12-17 | 2013-12-12 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738146P | 2012-12-17 | 2012-12-17 | |
US61/738,146 | 2012-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014099584A1 true WO2014099584A1 (en) | 2014-06-26 |
Family
ID=50979047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/074584 WO2014099584A1 (en) | 2012-12-17 | 2013-12-12 | Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment |
Country Status (3)
Country | Link |
---|---|
US (1) | US9527838B2 (en) |
EP (1) | EP2931718B1 (en) |
WO (1) | WO2014099584A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016149405A1 (en) * | 2015-03-16 | 2016-09-22 | Esperion Therapeutics, Inc. | Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk |
US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258701A1 (en) * | 2003-02-13 | 2006-11-16 | Banyu Pharmaceutical Co., Ltd. | Novel 2-pyridinecarboxamide derivatives |
US20080090799A1 (en) * | 2006-10-06 | 2008-04-17 | Noriaki Hashimoto | 2-pyridinecarboxamide derivative having gk-activating effect |
US20100261699A1 (en) * | 2007-12-25 | 2010-10-14 | Banyu Pharmaceutical Co., Ltd. | N-pyrazole-2-pyridine carboxamide derivative |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2008156174A1 (en) * | 2007-06-21 | 2010-08-26 | 大正製薬株式会社 | Pyrazineamide compound |
EP2931734B1 (en) | 2012-12-17 | 2020-12-02 | Merck Sharp & Dohme Corp. | Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
-
2013
- 2013-12-12 US US14/652,944 patent/US9527838B2/en active Active
- 2013-12-12 EP EP13865833.1A patent/EP2931718B1/en active Active
- 2013-12-12 WO PCT/US2013/074584 patent/WO2014099584A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258701A1 (en) * | 2003-02-13 | 2006-11-16 | Banyu Pharmaceutical Co., Ltd. | Novel 2-pyridinecarboxamide derivatives |
US20080090799A1 (en) * | 2006-10-06 | 2008-04-17 | Noriaki Hashimoto | 2-pyridinecarboxamide derivative having gk-activating effect |
US20100261699A1 (en) * | 2007-12-25 | 2010-10-14 | Banyu Pharmaceutical Co., Ltd. | N-pyrazole-2-pyridine carboxamide derivative |
Non-Patent Citations (1)
Title |
---|
KUMARI ET AL.: "Comparative Docking Assessment of Glucokinase Interactions with its Allosteric Activators.", CURRENT CHEMICAL GENOMICS, vol. 2, no. 1, 2008, pages 76 - 89, XP055028645 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US11744816B2 (en) | 2015-03-13 | 2023-09-05 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
WO2016149405A1 (en) * | 2015-03-16 | 2016-09-22 | Esperion Therapeutics, Inc. | Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk |
US11116739B2 (en) | 2015-03-16 | 2021-09-14 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease |
Also Published As
Publication number | Publication date |
---|---|
US9527838B2 (en) | 2016-12-27 |
EP2931718B1 (en) | 2019-01-16 |
US20150336946A1 (en) | 2015-11-26 |
EP2931718A1 (en) | 2015-10-21 |
EP2931718A4 (en) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011256444B2 (en) | Spiro isoxazoline compounds as SSTR5 antagonists | |
AU2009304508A1 (en) | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
US10065945B2 (en) | Isoquinoline derivatives as MGAT2 inhibitors | |
EP2760855B1 (en) | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes | |
AU2009299091A1 (en) | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
AU2017360939A1 (en) | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | |
US8759539B2 (en) | Substituted bicyclic amines for the treatment of diabetes | |
EP2931718B1 (en) | Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | |
WO2012015693A1 (en) | Imidazole derivatives | |
EP2931734B1 (en) | Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment | |
WO2013068328A1 (en) | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors | |
WO2012112364A1 (en) | Lactam derivatives as dgat-1 inhibitors | |
WO2012047772A2 (en) | Imidazole derivatives | |
WO2012122075A1 (en) | Lactam derivatives as dgat-1 inhibitors | |
US20150274664A1 (en) | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | |
WO2013130370A2 (en) | Compounds as dgat-1 inhibitors | |
WO2013068439A1 (en) | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13865833 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14652944 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013865833 Country of ref document: EP |